

Compendium of Clinical Studies

Er:YAG and Nd:YAG Laser Treatments
in Gynecology

June 2026



Content

- 4 Scientific Evidence Behind
Laser Gynecological Treatments
- 5 Short Drafts of Selected Scientific
Publications
- 71 List of Published Clinical Studies

Foreword

Scientific Evidence Behind Laser Gynecological Treatments

For over a decade, the Laser and Health Academy (LA&HA) has been at the forefront of supporting and conducting numerous scientific studies exploring the safety and effectiveness of laser-based applications, including the notable non-ablative Er:YAG SMOOTH gynecological laser therapy introduced in 2012. Published in esteemed, peer-reviewed international journals, these studies have yielded clinically proven results, showcased in more than 120 publications. Among these, a meta-analysis of randomized controlled trials (RCTs) confirm the effectiveness and safety of Fotona laser therapy for stress urinary incontinence (SUI), further strengthening the clinical credibility of laser-based therapy.

The newly updated compendium compiles the summaries of some of the most impactful published clinical studies that support the safety and efficacy of laser gynecological treatments using non-ablative Er:YAG SMOOTH and Nd:YAG PIANO laser technology. The first part of the compendium contains brief drafts from selected publications, outlining some of the key findings of each study. The second part presents the comprehensive collection of published studies, with QR codes added for easier access to the official online sources.

By encouraging the exchange and dissemination of scientific knowledge among peers, LA&HA strives to facilitate the widespread adoption of evidence-based laser medicine among the healthcare community and the general public. We believe this compendium will help bring crucial scientific evidence one step closer to users.

The LA&HA Clinical Affairs Team

The use of lasers for medical treatments is subject to local regulations, which may vary depending on your region. Please check with the manufacturer whether a specific product or application has been approved or cleared to be marketed in your country.

Short Drafts of Selected Scientific Publications



The Use of Energy-Based Devices for the Treatment of Stress Urinary Incontinence: A Systematic Review and Meta-Analysis of Randomised Sham-Controlled Trials

Authors: Lukanovic D, Shah G, Matjasic M, Phillips C

Published in: *International Urogynecology Journal*, 2026

1. EVALUATING ENERGY-BASED DEVICES FOR SUI TREATMENT

This study aimed to systematically evaluate the efficacy and safety of energy-based devices (EBDs), including vaginal laser and radiofrequency therapies, for the treatment of stress urinary incontinence (SUI) in women. The objective was to determine whether these minimally invasive therapies provide superior symptom improvement compared to sham treatment, with particular focus on validated patient-reported outcomes.

2. SYSTEMATIC REVIEW AND META-ANALYSIS OF SHAM-CONTROLLED RCTS

A systematic review and meta-analysis were conducted following PRISMA guidelines, including 10 randomized controlled trials (11 datasets) with approximately 850 women. Only sham-controlled studies were included to ensure methodological rigor. The primary outcome was change in ICIQ-UI SF scores. Over 2,600 studies were screened before selecting the final 10 trials. Subgroup analyses were performed for different device types, including non-ablative Er:YAG laser in SMOOTH® mode (Fotona, Slovenia), ablative Er:YAG and CO₂ lasers, and radiofrequency.

3. SYMPTOM IMPROVEMENT WITH EBDs

The meta-analysis demonstrated a small but statistically significant improvement in SUI symptoms with EBDs compared to sham, with a pooled mean difference of -1.08 in ICIQ-UI SF scores. However, results varied across studies, with moderate heterogeneity and a wide prediction interval indicating inconsistent effects. Subgroup analysis showed that non-ablative Er:YAG laser provided the most consistent and clinically meaningful benefit (mean difference -1.42), with lower heterogeneity compared to other modalities. In contrast, CO₂ laser results were inconsistent, and evidence for radiofrequency was limited.

4. FAVORABLE SAFETY PROFILE

Energy-based devices appear to be safe, with adverse events generally mild and transient. Current evidence suggests that non-ablative Er:YAG laser shows the most reliable outcomes, particularly in women with mild to moderate SUI.



Vaginal Erbium Laser for the Treatment of Mild-to-Moderate Stress Urinary Incontinence: A Multicentre Randomised Sham-Controlled Trial

1. EVALUATING ER:YAG LASER FOR MILD-TO-MODERATE SUI

This study aimed to determine whether non-ablative Er:YAG vaginal laser (Fotona, Slovenia) is superior to sham treatment in women with mild-to-moderate stress urinary incontinence (SUI). The rationale was based on the laser's ability to induce collagen remodeling and improve urethral support, offering a minimally invasive alternative to surgery for patients who do not respond to conservative therapy.

2. MULTICENTRE RANDOMISED SHAM-CONTROLLED TRIAL DESIGN

A single-blinded, multicentre randomized controlled trial included 79 women with mild-to-moderate SUI across three European urogynaecology centres. Participants were randomized in a 2:1 ratio to receive either three Er:YAG SMOOTH® laser treatments or sham procedures, with follow-up at 6 months. The primary outcome was cure defined as at least a 50% reduction in pad weight test (PWT), with secondary outcomes including ICIQ-UI SF, PISQ-12, and clinical assessments.

3. SIGNIFICANT IMPROVEMENT IN OBJECTIVE AND SUBJECTIVE OUTCOMES

The laser group demonstrated significantly higher cure rates compared to sham (62.7% vs. 18.2%). There were statistically and clinically significant improvements in objective and subjective measures, including reductions in pad weight, improvement in ICIQ-UI SF scores (median reduction of 5 points), and increased PISQ-12 scores. In contrast, the sham group showed no meaningful improvement in most outcomes. These findings indicate that Er:YAG laser provides both symptomatic relief and quality-of-life benefits in this patient population.

4. EFFECTIVE, SAFE, AND MINIMALLY INVASIVE TREATMENT OPTION

Non-ablative Er:YAG laser treatment was well tolerated, with only mild and transient adverse effects and no serious complications reported. The results support its use as a safe and effective short- to medium-term treatment for mild-to-moderate SUI, particularly for patients seeking alternatives to surgery.

Authors: Phillips C, Shah

G, Gamper M, Kuszka A,

Chandrakumaran K, Viereck V

-

Published in: International

Journal of Obstetrics &

Gynaecology, 2025



Outcomes at 6 months follow up.

Variable	Baseline	Six months	<i>p</i>
<i>Primary outcome</i>			
50% reduction in PWT (%)	NA	<i>N</i> /Total. %	
Laser	NA	32/51 62.7%	
Sham		4/23 18.2%	
<i>p</i> value between		<0.001^a	
<i>Secondary outcomes</i>			
PWT (Median, IQR)	5.0 g (3.27)	1.4 g (3.75)	0.002^b
Laser (<i>n</i> =51)	9.0 g (8.6 ^c)	8.0 g (10.8)	0.761 ^b
Sham (<i>n</i> =23)	0.032^a	<0.001^a	
ICIQ-UI SF (Median, IQR)			
Laser (<i>n</i> =51)	13 (4.0)	8 (4.5)	<0.001^b
Sham (<i>n</i> =23)	14 (3.5)	11 (6.5)	0.415 ^b
	NS	NS	
PISQ-12 (Median, IQR)			
Laser (<i>n</i> =48)	33 (8.25)	39 (7.00)	<0.001^b
Sham (<i>n</i> =23)	30 (8.25)	32.5 (9.25)	0.039^b
	NS	0.001^a	

PWT, pad weight test

p<0.05, statistically significant. NS, not significant.

^aMann-Whitney U test.

^bWilcoxon Signed Rank test.

Vaginal Erbium Laser Versus Pelvic Floor Muscle Training for Stress Urinary Incontinence: A Randomised Controlled Trial

1. COMPARING LASER AND PFMT FOR STRESS URINARY INCONTINENCE (SUI)

This randomized controlled trial aimed to compare the effectiveness of non-ablative vaginal Er:YAG laser therapy with pelvic floor muscle training (PFMT) in women with mild to moderate stress urinary incontinence (SUI). The study assessed whether laser therapy could serve as a viable alternative to PFMT, focusing on symptom relief, patient satisfaction, and long-term effectiveness over two years.

2. RANDOMIZED TRIAL WITH LASER AND PFMT GROUPS

A total of 60 women diagnosed with mild to moderate SUI were randomized into two groups: one receiving three to six laser treatments (SP Spectro, Fotona, Slovenia) and the other undergoing a structured PFMT program with nine to eighteen sessions. The primary outcome was symptom improvement at four months, measured by the Urogenital Distress Inventory-6 (UDI-6). Secondary outcomes included patient-reported quality of life, treatment satisfaction, and adverse events, with follow-ups extending to 24 months.

3. SHORT-TERM IMPROVEMENT WITHOUT SIDE EFFECTS

Both groups showed significant symptom improvement at four months, with no subjective or objective inter-group differences, confirming laser's non-inferiority to PFMT. No serious adverse effects occurred in either group.

4. LASER MATCHES PFMT FOR SYMPTOM RELIEF

The study concluded that laser therapy and PFMT offer comparable short-term benefits for mild to moderate SUI.

Authors: Page A-S, Borowski E, Bauters E, Housmans S, Van der Aa F, Deprest J
-
Published in: International Urogynecology Journal, 2025



Efficacy and Safety of Non-Ablative Er:YAG Laser for Mild to Moderate Stress Urinary Incontinence: A Prospective, Multicenter, Randomized, Sham-Controlled Clinical Trial

Authors: Wang X, Zhang Z, Meng L, Xu S, Zheng Z, Wang H, Lv J, Zhang Z, Yuan X, Zhang Y

Published in: *Lasers in Medical Science*, 2025

1. EVALUATING LASER THERAPY FOR SUI

The study aimed to evaluate the efficacy and safety of non-ablative vaginal Er:YAG laser therapy in treating women with mild to moderate stress urinary incontinence (SUI). It also sought to provide more rigorous clinical data using a randomized, sham-controlled design in a Chinese patient population.

2. RIGOROUS MULTICENTER CLINICAL TRIAL DESIGN

A prospective, multicenter, randomized, sham-controlled clinical trial was conducted across four Chinese medical centers between 2020 and 2023. A total of 125 women diagnosed with mild to moderate SUI were randomized in a 2:1 ratio to receive either three monthly sessions of Er:YAG laser therapy (XS Dynamis, Fotona, Slovenia) or sham treatment. Efficacy was assessed using objective (urine pad test) and subjective (ICIQ-SF, I-QOL) outcomes over a three-month follow-up period.

3. SIGNIFICANT IMPROVEMENT WITH LASER TREATMENT

At three months post-treatment, the laser group showed a 71.43% treatment success rate versus 36.59% in the sham group, with a significant absolute difference of 34.84%. While both groups improved on quality-of-life and symptom severity scales, only the laser group showed significantly greater objective reductions in urinary leakage and incontinence frequency. Adverse events were mild and transient, mostly limited to discomfort and temporary discharge.

4. PROMISING NON-SURGICAL OPTION FOR SUI

Non-ablative Er:YAG laser therapy demonstrated significant short-term benefits in treating SUI, offering a non-invasive alternative with good safety and tolerability.



Urinary symptoms data between two groups after treatment.

	Experimental group (n = 84)	Control group (n = 41)	P
Treatment succes at 1 month after treatment, n (%)	56 (70.00%)	15 (38.46%)	= 0.001
Reduce rate of one hour urine pad test with leakage			
1 month after treatment	43%	31%	<0.05
3 months after treatment	45%	14%	<0.001
Reduce frequencies of UI compared to baseline			
1 month after treatment (Mean ± SD)	1.79 ± 4.05	0.24 ± 3.70	<0.05
3 month after treatment (Mean ± SD)	1.63 ± 4.61	2.08 ± 4.08	<0.05

Combination of Non-Ablative Er:YAG Laser and Magnetic Stimulation for the Treatment of Urinary Incontinence: A Single-Arm Pilot Study

Authors: Strumbelj T

& Logar T

-

Published in: *European Gynecology and Obstetrics*, 2025

Combination of non-ablative Er:YAG laser and magnetic stimulation for the treatment of urinary incontinence: A single-arm pilot study

Tadeja Strumbelj¹, Tina Logar²

¹Obstetrics and Gynecology, University of Ljubljana, Slovenia

²Obstetrics and Gynecology, University of Ljubljana, Slovenia

A PDF file of supplementary material for this paper is available at <https://www.eurogynobstetrics.com/doi/10.1016/j.eurogynobstetrics.2025.1000000>

ABSTRACT

Objective: To assess the effectiveness and safety of combining non-ablative Er:YAG laser with a magnetic stimulation device for treating stress or mixed urinary incontinence.

Methods: In a prospective, single-arm pilot trial, 24 women with stress urinary incontinence (SUI) or mixed urinary incontinence (MUI) were treated with three intravaginal Er:YAG laser sessions and six high intensity Tesla magnetic stimulation (HITS) sessions. The primary objective was to improve incontinence symptoms, as measured by changes in the International Consultation on Incontinence Questionnaire (ICIQ) Urinary Incontinence Short Form (ICIQ-UI SF) and the Quantitative Urinary Incontinence Symptom Score (QUIS) scores from baseline. Secondary objectives included improvement in sexual function as assessed by Female Sexual Function Index (FSFI) scores, pelvic floor muscle strength as measured by perineal muscle strength (PMS) and the presence of adverse effects.

Results: At baseline, one third of participants had moderate SUI and over 60% had severe SUI. After treatment with the Er:YAG laser and HITS, significant symptom improvements were observed. At 6 months, ICIQ-UI SF scores decreased significantly from 12.46 to 5.48, and QUIS scores decreased significantly from 12.46 to 5.48. FSFI scores increased significantly from 12.46 to 18.46. PMS scores increased significantly from 12.46 to 18.46. Over 90% of the patients with moderate to severe SUI, MUI, or mixed urinary incontinence reported subjective improvement, and approximately 13% became symptom-free at 6 months. The treatment was well tolerated with minimal adverse effects.

Conclusion: The combination of non-ablative Er:YAG laser and HITS effectively and safely improved SUI and MUI symptoms in adult women.

KEYWORDS: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

Epidemiological studies estimate the prevalence of urinary incontinence at 25% to 30% in young adults and 40% in older women⁵.

The etiology of SUI is multifactorial, involving weakened pelvic floor muscles and increased abdominal pressure⁶. SUI is associated with comorbidities including cognitive and psychological distress, reduced quality of life, and decreased sexual satisfaction^{7,8}. Pelvic floor muscle training (PFMT) is the recommended first-line therapy for SUI, and when combined with lifestyle changes, it can improve outcomes⁹. While PFMT addresses a subset of cases, in 30% of cases, further treatment is required for symptom relief and long-term management¹⁰.

Article history: Received 15 May 2025; Accepted 22 July 2025

Corresponding author: Tadeja Strumbelj, tadeja.strumbelj@upl.si

DOI: <https://doi.org/10.1016/j.eurogynobstetrics.2025.1000000>

Keywords: Combined therapy, Er:YAG laser, magnetic stimulation, non-ablative erbium laser, stress urinary incontinence.

Introduction

Urinary incontinence is a common and distressing condition affecting a significant proportion of women worldwide¹⁻³. Stress urinary incontinence (SUI) involves involuntary urine loss during physical activity or conditions that increase intra-abdominal pressure such as coughing or sneezing. Urge urinary incontinence (UUI) is the inability to hold urine until the next toilet visit, while mixed urinary incontinence (MUI) combines both types⁴.

1. FIRST STUDY OF A COMBINED LASER AND MAGNETIC STIMULATION THERAPY FOR STRESS & MIXED URINARY INCONTINENCE

This study aimed to assess the effectiveness and safety of combining non-ablative Er:YAG laser therapy (TimeWalker® IntimaLaser™, Fotona, Slovenia) with High Intensity Tesla magnetic stimulation (HITS) (StarFormer® IntimaWave®, Fotona, Slovenia) for the treatment of stress urinary incontinence (SUI) and mixed urinary incontinence (MUI) in adult women. The rationale was that laser therapy targets connective tissue remodeling, while magnetic stimulation strengthens pelvic floor muscles, potentially providing complementary therapeutic effects.

2. COMBINED LASER + HITS TREATMENT APPROACH

A prospective single-arm pilot study was conducted on 24 women with SUI or MUI (predominantly SUI). Participants underwent three intravaginal IncontiLase® laser sessions with, followed by six HITS treatments. Outcomes were assessed using validated questionnaires including ICIQ-UI SF and QUID for symptom severity, and FSFI for sexual function, along with clinical evaluation of pelvic floor muscle strength.

3. SIGNIFICANT SYMPTOM IMPROVEMENT


The combined therapy resulted in significant reductions in urinary incontinence severity, with ICIQ-UI scores decreasing from 12.46 to 5.48 at 6 months. Symptom severity shifted from predominantly moderate and severe cases at baseline to mostly mild or no symptoms at follow-up. Improvements were observed in both SUI and urge urinary incontinence (MUI) components, with HITS contributing additional benefits after laser treatment. Pelvic floor muscle strength improved in over 70% of patients, and sexual function scores increased significantly. More than 90% of participants reported subjective improvement, and approximately 13% became symptom-free at 6 months.

4. COMBINED THERAPY AS A SAFE AND SYNERGISTIC TREATMENT OPTION


The combination of non-ablative Er:YAG laser and magnetic stimulation appears to be a safe and effective treatment for urinary incontinence, with sustained benefits up to 6 months. The therapies act synergistically by addressing both tissue structure and muscle function. Treatment was well tolerated with minimal adverse effects.



OPEN ACCESS



Treatment plan: Patients received three monthly laser sessions starting at baseline (T0), followed 6 weeks later by six HITS sessions at 3-4-day intervals (T1-T2). Follow-up examinations were performed 3 months (T3) and 6 months (T4) after the last HITS session.



Effect of treatment on SUI severity based on ICIQ-UI SF scores. Baseline (T0), after laser and before HITS therapy (T1), after HITS therapy (T2), 3 months (T3) and 6 months (T4) follow ups.

Combined Intraurethral and Intravaginal Er:YAG Laser (UEL+VEL) vs. Intraurethral (UEL) Alone for Stress Urinary Incontinence: A Multicenter Retrospective Cohort Study

Authors: Erel CT, Ozcivit

Erkan IB, Gokmen N,

Gambacciani M, Gaspar

A, Lazzaretta L, Okui N,

Pustotina O, Senturk LM,

Tas IS, Gungor Ugurlucan F,

Yasa C, Urfalioglu M

Published in: *Lasers in*

Medical Science, 2025



1. EVALUATING COMBINED LASER THERAPY FOR SUI AND MUI

This study aimed to compare the effectiveness of combined intraurethral and intravaginal non-ablative Er:YAG laser (UEL+VEL) versus intraurethral laser alone (UEL) in women with stress urinary incontinence (SUI) and stress-dominant mixed urinary incontinence (MUI). The rationale was that targeting both urethral and vaginal tissues may enhance structural support and improve continence outcomes.

2. MULTICENTER RETROSPECTIVE COHORT STUDY DESIGN


A multicenter retrospective cohort study included 228 women who were treated with Fotona's SP Dynamis® laser, with 161 receiving combined UEL+VEL and 67 receiving UEL alone. Patients were treated across multiple international centers and followed for 12 months. The primary outcome was change in ICIQ-UI SF scores measured at baseline, 3, 6, and 12 months. Baseline characteristics were generally comparable, although baseline symptom severity and parity differed between groups.

3. GREATER SYMPTOM IMPROVEMENT WITH COMBINED THERAPY

Both treatment groups demonstrated significant improvement in urinary incontinence symptoms over time. However, the combined UEL+VEL group showed a greater and more sustained reduction in ICIQ-UI SF scores, particularly at 6 months, where scores were significantly lower compared to UEL alone. The UEL+VEL group exhibited a steeper decline in symptom severity over time, eventually converging with the UEL group at 12 months but with a greater overall improvement. Parity was identified as a significant factor influencing treatment outcomes, with higher parity associated with differential responses.

4. COMBINED APPROACH AS A MORE EFFECTIVE TREATMENT STRATEGY

Both UEL and UEL+VEL therapies were safe and effective for improving SUI and stress-dominant MUI symptoms, with benefits sustained up to 12 months. However, combined therapy demonstrated superior efficacy, particularly in patients with more severe symptoms or higher parity.



An algorithm for the management of patients with SUI using non-ablative Er: YAG laser therapy (MUS: mid-urethral sling; PFMT: pelvic floor muscle training; UEL: intraurethral Er:YAG laser; VEL: vaginal Er:YAG laser).

Vaginal Erbium Laser Treatment for Stress Urinary Incontinence: A Multicenter Randomized Sham-Controlled Clinical Trial

Authors: O'Reilly BA,
Viereck V, Phillips C,
Tooze-Hobson P, Kuhn A,
Athanasios S, Lukanovic A,
Palmer B, Dahly D, Daykan Y,
Cardozo L

Published in: *International Journal of Gynecology and Obstetrics*, 2023



1. EXAMINING THE EFFICACY AND SAFETY OF ER:YAG LASER FOR SUI TREATMENT

The aim of this multicenter study was to evaluate the efficacy and safety of non-ablative vaginal Er:YAG laser for the treatment of stress urinary incontinence (SUI).

2. 110 PARTICIPANTS IN A BLINDED RANDOMIZED SHAM-CONTROLLED TRIAL


During this multicenter trial 110 participants with SUI were recruited, with 73 in an active arm and 37 in a sham arm. Patients received two treatments (XS Dynamis, Fotona, Slovenia) at 1 month apart. The primary outcome measure was the 1 h pad weight test measured at 6 months. Secondary outcomes were the durability of treatment success at 12 months, and questionnaires that assessed SUI severity (ICIQ-UI SF), sexual function (PISQ-12) and HRQoL (KHQ), and incidence and severity of device-related adverse events and pain (VAS).

3. RESULTS SHOW SIGNIFICANTLY HIGHER IMPROVEMENT IN THE ACTIVE ARM

The primary outcome data obtained from the trial revealed that treatment success was observed in 36% of the sham arm compared to 59% of the active arm that received Er:YAG laser treatment. Subjective patient assessment of general and sexual function improvement with PISQ-12 and PGI-I also showed superior effects compared to the sham (OR 2.8, 95% CI: 1.2–7.0, $P = 0.02$ and OR 0.13, 95% CI: 0.05–0.36, $P < 0.001$, respectively).

4. A SUCCESSFUL TREATMENT OPTION FOR SUI PATIENTS

The authors of the study conclude that non-ablative vaginal Er:YAG laser appears to be a safe and effective non-surgical treatment option for SUI, with a superior effect over sham as measured by the primary outcome measure, the 1-h pad weight test.



Treatment success demonstrated as log transformed pad weight at baseline and at 6 months follow-up (FU) in a control and laser arm. Green line – participants with treatment success >50% pad weight reduction from baseline at FU, gray lines – participants without treatment success. Dashed lines identifies the median.

Efficacy and Safety of Intraurethral Er:YAG Laser Treatment in Women with Stress Urinary Incontinence Following Failed Intravaginal Laser Therapy: A Retrospective Study

Authors: Tseng YL & Su CF

Published in: *Lasers in Medical Science*, 2023



1. EVALUATING INTRAURETHRAL ER:YAG LASER TREATMENT FOR FAILED INTRAVAGINAL THERAPY

This was a retrospective study that included 93 female patients with mild to moderate stress urinary incontinence (SUI) who had completed two courses of intravaginal Er:YAG laser treatment (SP Dynamis, Fotona, Slovenia) between January 2015 and June 2018. Of these patients, 22 (23%) who continued to experience persistent SUI at 4 weeks following the second intravaginal Er:YAG laser treatment were selected to receive intraurethral laser treatment in January 2019.

2. COMPARISON OF PRE- AND POST- INTRAURETHRAL TREATMENT ICIQ-UI SF SCORES


The 22 female patients with persistent SUI received intraurethral Er:YAG laser treatment using Er:YAG SMOOTH technology via a 4-mm cannula with fluence of 1.5 J/cm². Their average age was 47.5 years, with an average of 2 parities and a mean body mass index of 20.97. All patients completed the ICIQ-SF questionnaire before and 3 months after the procedure.

3. MAJORITY OF PATIENTS REPORTED IMPROVEMENT IN SYMPTOMS

Of the patients, 77% reported improvement in symptoms, with 6 reporting strong improvement and 11 reporting improvement. The treatment was well-tolerated, with mild and transient adverse effects such as urinary infection in 1 patient (4.5%) and mild pain in 7 patients (31.8%).

4. A PROMISING ALTERNATIVE FOR PATIENTS WITH PERSISTENT SUI

Intraurethral laser treatment may be helpful for many women with persistent SUI after vaginal laser treatment. Using intraurethral Er:YAG SMOOTH laser treatments to rejuvenate tissues and enhance structural support could be a promising avenue for managing stress urinary incontinence.



Improvement ratio after intraurethral laser treatment.

SUI in Postmenopausal Women: Advantages of an Intraurethral + Intravaginal Er:YAG Laser

1. INTRAURETHRAL + INTRAVAGINAL LASER TREATMENT FOR POSTMENOPAUSAL SUI

This study aimed to compare the efficacy of concomitant application of an intraurethral (IU) + intravaginal (IV) non-ablative Er:YAG laser with IV application in improving the symptoms of stress urinary incontinence (SUI) in women.

2. 122 SUI PATIENTS TREATED WITH ER:YAG LASER (62 WITH IU + IV AND 62 WITH IV ONLY)


This observational retrospective cohort study included 122 SUI patients, 60 women in the IU + IV laser arm and 62 in the IV laser arm. The primary outcome was the International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form (ICIQ-UI SF) score at entry and at 3, 6 and 12 months from baseline. The IV Er:YAG laser procedure (SP Dynamis, Fotona, Slovenia) was applied according to the setting for SUI. The IU SMOOTH mode Er:YAG laser was applied according to a procedure previously described by Gaspar and Brandi. Pelvic examination and ultrasound were done and a vaginal smear test was taken before the intervention. SUI was diagnosed by the history and pelvic examination along with the stress and Q-tip test.

3. CONCOMITANT APPLICATION OF IU + IV ER:YAG LASER SHOWED GREATER IMPROVEMENT

The results of the study showed that significant improvement in SUI symptoms was seen 3 months after the intervention and was sustained until the end of month 12 in both arms. The women who had severe SUI symptoms initially showed greater improvement. A higher number of women who initially had mild to moderate SUI symptoms were dry after treatment. Patients treated with IU + IV Er:YAG laser showed significant improvement in SUI symptoms compared to IV laser only, especially at postmenopausal state ($p = 0.003$).

4. COMBINED IU + IV LASER TREATMENT IS EFFECTIVE FOR POSTMENOPAUSAL SUI

Non-ablative Er:YAG laser appears to be an efficient method for the treatment of SUI. Concomitant application of an IU + IV Er:YAG laser is more effective in relieving SUI symptoms at a postmenopausal state.



Improvement in SUI symptoms in relation to treatment method – intraurethral (IU) + intravaginal (IV) vs. intravaginal (IV) alone.

Authors: Erel CT, Gambacciani M, Ozcivit Erkan IB, Gokmen Inan N, Hamzaoglu Canbolat K, Fideicichi T

Published in: Climacteric, 2023



Vaginal Er:YAG Laser for Treatment of Stress Urinary Incontinence: Optimization of Treatment Regimen for a Sustained Long-Term Effect

Authors: Gaspar A, Koron N,
Silva J, Brandi H

-

Published in: *Lasers in Medical
Science*, 2022



OPEN  ACCESS



1. ASSESSING THE LONG-TERM EFFICACY AND SAFETY OF ER:YAG LASER TREATMENT OF SUI

This prospective uncontrolled study was conducted to assess the long-term efficacy and safety of non-ablative Er:YAG laser treatment of Stress urinary incontinence (SUI), a common health problem that affects roughly 35% of women in the reproductive period.

2. FORTY-THREE SUI PATIENTS UNDERWENT THREE SESSIONS OF INCONTILASE®

The patients received three consecutive non-ablative Er:YAG laser (XS Dynamis, Fotona, Slovenia) treatments with 20-day intervals between sessions following the IncontiLase® protocol. The efficacy of laser treatment was assessed by 1-h pad test, 24-h pad test, 3-day voiding diary, and ICIQ-UI SF questionnaire at multiple follow-ups. Statistical analysis was performed using one-way repeated measures ANOVA. Patients were questioned about discomfort during treatment and any adverse events following the laser procedures.

3. RESULTS SHOW A SIGNIFICANT IMPROVEMENT OF SUI SYMPTOMS

All outcome measures showed a significant change over a period of the entire clinical trial. The eighteen-month follow-up revealed a fading of the effect, which was alleviated by single-session maintenance treatments every 6 months. There were no serious adverse events reported during the study. All reported side effects were mild and transient.

4. NON-ABLATIVE ER:YAG LASER IS AN EFFICACIOUS AND SAFE OPTION FOR TREATMENT OF SUI

The results of this study show that application of non-ablative Er:YAG laser for SUI treatment significantly improves SUI symptoms. High improvement rates and patient satisfaction can be maintained with single-session maintenance treatments performed every 6 months.

Improvement in outcome measures at three different time points (follow-ups). Data is presented as the percentage of patients with a corresponding improvement rate (n = number of patients).

Outcome Measure	ICIQ-UI SF			1-h pad test		
	All (n = 43)	Group 1 (n = 28)	Group 2 (n = 15)	All (n = 43)	Group 1 (n = 28)	Group 2 (n = 15)
6-month FU						
Dry ^a (%)	14	19	7	0	0	0
Improved ^b (%)	81	81	80	21	4	53
Not improved ^c (%)	5	0	13	79	96	47
Worse ^d (%)	0	0	0	0	0	0
Dry or improved (%)	95	100	87	21	4	53
12-month FU	(n = 43)	(n = 28)	(n = 15)	(n = 43)	(n = 28)	(n = 15)
Dry ^a (%)	14	18	7	0	0	0
Improved ^b (%)	53	54	13	40	25	67
Not improved ^c (%)	33	28	80	60	75	33
Worse ^d (%)	0	0	0	0	0	0
Dry or improved (%)	67	72	20	40	25	67
36-month FU	(n = 34)	(n = 21)	(n = 13)	(n = 34)	(n = 21)	(n = 13)
Dry ^a (%)	76	90	54	0	0	0
Improved ^b (%)	24	10	46	50	38	69
Not improved ^c (%)	0	0	0	50	62	31
Worse ^d (%)	0	0	0	0	0	0
Dry or improved (%)	100	100	100	50	38	69

ICIQ-UI SF International Consultation on Incontinence Questionnaire—Urinary Incontinence Short Form, FU follow-up

^a1-h pad test < g, or ICIQ-UI SF score = 0

^bIf improvement at the follow-up was ≥ 50%

^cIf improvement at the follow-up was < 50%

^dIf improvement at the follow-up was negative (relative to baseline)

Changes in Sexual Function and Vaginal Topography using Transperineal Ultrasound after Vaginal Laser Treatment for Women with Stress Urinary Incontinence

Authors: Long C-W, Wu P-C,
Chen H-S, Lin K-L, Loo Z,
Liu Y, Wu C-H

Published in: *Scientific Reports*, 2022

1. ASSESSING THE EFFECTS OF ER:YAG VAGINAL LASER TREATMENT FOR SUI

This study aims to assess the changes in sexual function and vaginal topography using 3-D transperineal ultrasound in stress-incontinent women treated with Er:YAG vaginal laser.

2. A 6-MONTH STUDY USING VAGINAL TOPOGRAPHY AND 3-D TRANSPERINEAL ULTRASOUND

Two hundred and twenty women with stress urinary incontinence (SUI) treated with Er:YAG laser (FotonaSmooth XS, Fotona, Slovenia) were recruited. Assessment before and 6 months after the treatment included vaginal topography using 3-D transperineal ultrasound and sexual function using female sexual function index questionnaire (FSFI).


3. RESULTS SHOW SYMPTOMATIC IMPROVEMENT IN 74% OF WOMEN

A total of 50 women with complete data showed that the symptomatic improvement was noted in 37 (74%) women. After the Er:YAG vaginal laser treatment, a significantly decreased width and cross-sectional area in the proximal, middle, and distal vagina were found in women with SUI. Nearly all of the domains of FSFI improved significantly after the vaginal laser treatment, except sexual desire.

4. ER:YAG VAGINAL LASER TREATMENT PRODUCES FAVORABLE ANATOMICAL CHANGES

The study shows that following Er:YAG vaginal laser treatment, the anatomical changes of vaginal shrinkage and an improvement of female sexual function were both noted. The favorable outcome of sexual function partly related to the tightening of the vagina, as evidenced by the measurements of the 3-D transperineal ultrasound.





The sequential images of vaginal width and area of a same patient before and after treatment at different levels of vagina.

Comparison of Urethral Sling Surgery and Non-ablative Vaginal Er:YAG laser Treatment in 327 Patients with Stress Urinary Incontinence: A Case-matching Analysis

Authors: Okui NP, Miyazaki H, Takahashi W, Miyauchi T, Ito C, Okui M, Shigemori K, Miyazaki Y, Vizintin Z, Lukac M

-

Published in: *Lasers in Medical Science*, 2021

1. FIRST PS ANALYSIS COMPARING TVT AND VAGINAL ERBIUM:YAG LASER TREATMENT (VEL)

This study, published in *Lasers in Medical Science*, retrospectively compared tension-free vaginal tape (TVT) and non-ablative vaginal Erbium:YAG laser treatment (VEL) by propensity score (PS) analysis in women with SUI. No previous PS analysis studies have investigated urethral sling surgery using polypropylene TVT and VEL for SUI.

2. STUDY EXAMINED A LARGE NUMBER OF PATIENTS AT SEVERAL FACILITIES

The study analyzed 102, 113, and 112 patients in the TVT, VEL, and control groups, respectively. The subjects were patients between 35 and 50 years of age at the time of treatment who (1) underwent TVT surgery, (2) received VEL treatment (XS Dynamis, Fotona, Slovenia) or (3) were placed under observation with no treatment (control) for SUI at several facilities, within a period of 15 years between 2004 and 2019. The choice of treatment type (VEL or TVT) was up to the patients after the consultations, at which they were informed in detail about both options.

3. RESULTS SHOW SIGNIFICANT IMPROVEMENT

Compared with the control group, the TVT and vaginal erbium laser VEL groups exhibited significant improvement in the 1-h pad test and ICIQ-SF. In the PS analysis, the TVT and VEL groups similarly improved in the 1-h pad test and ICIQ-SF. As for the OABSS, the VEL group showed significantly greater improvement than the TVT group.


4. A VIABLE OPTION FOR SUI TREATMENT

The results of this study demonstrate that vaginal Erbium:YAG laser (VEL) is a viable option for patients desiring SUI treatment. VEL may be an option for patients with both SUI and OAB symptoms, as TVT can worsen urinary urgency and frequency, and VEL could represent an option for patients who are concerned about artificial implants.



OPEN ACCESS





Treatment in the TVT and VEL groups. (a) The number of patients at 0, 3, 6, 9 and 12 months in three groups. (b-d) The change over time for the 1-h pad test, ICIQ-SF, and OABSS. There was a significant difference between the start of treatment and 1-year post-treatment in the TVT and VEL groups. No significant difference was observed in the control. Only OABSS was significantly different between the two groups.

Er:YAG Laser Treatment of Urinary Incontinence After Failed TOT/TVT Procedures

Authors: Erel CT, Carazo Fernandez LD, Inan D, Makul M

Published in: *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 2020



1. EVALUATING THE USE OF ER:YAG LASER FOR SUI AFTER FAILED TOT/TVT PROCEDURES

This study was performed to determine if non-ablative Er:YAG laser treatment can improve the symptoms of SUI patients who had previously experienced failed TOT/TVT procedures.

2. A RETROSPECTIVE STUDY WITH DATA FROM TWO OBSTETRICS AND GYNECOLOGY DEPARTMENTS

The retrospective study included 25 women with persistent SUI after failed TOT/TVT operations and 25 women who previously did not receive either any type of surgical or non-invasive treatment for SUI.


2940 nm Er:YAG laser (SP Spectro Dynamis, Fotona, Slovenia) was used in the treatment procedure for SUI. The patients were evaluated on the basis of ICIQ-SF before and after the procedure. According to the differences in the ICIQ-SF before and after, the percentage of improvement was graded as “good responders” ($\geq 50\%$) or “poor responders” ($< 50\%$). The duration of the treatment effect was evaluated in follow-ups with relation to maximum improvement time (MIT) and total improvement time (TIT).

3. RESULTS SHOW SIGNIFICANT IMPROVEMENT

The SUI patients who previously had failed TOT/TVT operations had a significantly higher initial ICIQ-SF score ($p = 0.013$). Non-ablative Er:YAG laser treatment significantly and similarly improved the severity of SUI symptoms in both groups ($p = 0.000$ for failed TOT/TVT group and $p = 0.001$ for the non-TOT/TVT group, respectively). The women who were good responders were younger ($p = 0.012$) and had fewer years in menopause ($p = 0.011$). The effect of Er:YAG laser treatment lasted longer among the SUI women in the good responders group ($p = 0.000$ for MIT and $p = 0.000$ for TIT, respectively).

4. A PROMISING OPTION FOR SUI PATIENTS WITH FAILED TOT/TVT PROCEDURES

Non-ablative Er:YAG SMOOTH mode laser is an alternative choice of treatment for the SUI patients who previously had failed TOT/TVT procedures. Its effect lasts longer especially in younger and early postmenopausal women.



Mean ICIQ-SF scores in the TOT/TVT and non-TOT groups before and after the non-ablative Er:YAG laser treatment.

Predictive Factors for the Efficacy of Er:YAG Laser Treatment of Urinary Incontinence

1. DETERMINING THE PREDICTIVE FACTORS FOR ER:YAG LASER TREATMENT OF UI

The aim of this study was to determine the efficacy and predictive factors for the success of Er:YAG laser treatment in patients with urinary incontinence (UI).

Authors: Erel CT,
Inan D, Mut A

Published in: *Maturitas*, 2020

2. EIGHTY-TWO PATIENTS TREATED AND EVALUATED BY ICIQ-SF AND KHQ-UI

Eighty-two patients with UI were treated by Er:YAG laser (SP Spectro Dynamis, Fotona, Slovenia) in this cohort study. The patients were evaluated by ICIQ-UI SF and KHQ before and after the procedure. Improvement was categorized as: none (0-25%), mild (26-50%), moderate (51-75%), or high (76-100%). The duration of the treatment effect was evaluated at follow-up in relation to the maximum improvement time (MIT) and total improvement time (TIT).

3. RESULTS SHOW SIGNIFICANT IMPROVEMENT, ESPECIALLY WITH YOUNGER PATIENTS

Forty-two patients were determined to have SUI and 40 patients MUI. The mean ICIQ-UI SF and KHQ scores significantly improved after the procedure ($p < 0.0001$). The SUI patients responded to the laser treatment significantly better ($p < 0.008$). Younger women had significantly better results ($p < 0.008$), while premenopausal women ($p < 0.032$) and women in the early postmenopausal years ($p < 0.032$) also saw a positive response to the Er:YAG laser treatment. Women with a lower BMI had greater improvement ($p < 0.011$). The total laser energy expenditure during the sessions may also be a predictive parameter for the success of Er:YAG laser treatment of UI ($p = 0.059$). MIT and TIT were significantly longer among the patients in the high-improvement group.

4. ER:YAG LASER IS A SAFE AND EFFECTIVE TREATMENT FOR UI

Er:YAG laser treatment of the symptoms of UI, especially SUI, is more efficacious and of longer duration for younger, premenopausal or early postmenopausal women with normal BMI.



Er:YAG Laser in Hysterectomized Women with Stress Urinary Incontinence: A VELA Retrospective Cohort, Non-inferiority Study

Authors: Erel CT,
Fistonic I, Gambacciani M,
Oner Y, Fistonic N

Published in: *Climacteric*, 2020

1. FIRST PS ANALYSIS COMPARING TVT AND VAGINAL ERBIUM:YAG LASER TREATMENT (VEL)

Many studies have confirmed the efficacy of Er:YAG SMOOTH® laser in the treatment of SUI, however, this retrospective cohort, non-inferiority study offers the first published data on laser treatment of SUI in hysterectomized women.

2. A MULTICENTER VELA STUDY CONDUCTED AT THREE OBSTETRICS/ GYNECOLOGY CLINICS

In this real-world, retrospective cohort study performed in Turkey, Croatia and Italy, a consecutive sample of 35 hysterectomized and 34 non-hysterectomized patients with SUI were treated with Er:YAG SMOOTH® laser (SP Spectro Dynamis, Fotona, Slovenia). All three centers are members of VELA (Vaginal Er:YAG SMOOTH® Laser Academy), which defined the criteria, procedures, the common informed consent form and instruments for measuring clinical outcomes.

3. RESULTS SHOW SIGNIFICANT IMPROVEMENT


The results of this study supported the hypothesis of non-inferiority of intravaginal Er:YAG SMOOTH® laser treatment efficacy on the symptoms of SUI in hysterectomized women compared to its already proven efficacy in non-hysterectomized patients. The primary outcome was median reduction of SUI symptoms measured by the International Consultation on Incontinence Questionnaire—Urinary Incontinence Short-Form (ICIQ-SF). In hysterectomized patients, the ICIQ-SF was reduced by 5 points (95% confidence interval 3–8; $p < 0.001$), a reduction of 45% (95% confidence interval 36–67%).

4. A VIABLE OPTION FOR SUI TREATMENT IN HYSTERECTOMIZED WOMEN

Based on the results of this study, Er:YAG SMOOTH® laser treatment appears to improve the symptoms of SUI in hysterectomized women to approximately the same degree clinically as in non-hysterectomized women.



OPEN ACCESS



The median ICIQ-SF scores in hysterectomized and non-hysterectomized women before and after the Er:YAG SMOOTH® treatment.

Er:YAG Laser Treatment of Female Stress Urinary Incontinence: Midterm Data

1. EXAMINING EFFECTS OF SUI SEVERITY AND NUMBER OF LASER INTERVENTIONS

This study examined how incontinence severity at baseline and the number of laser interventions may affect the treatment success rate, and whether the effect of laser therapy was obvious 6 months and 2 years after the final laser intervention.

2. THREE STAGES OF SUI TREATED WITH THE INCONTILASE® PROTOCOL


Fifty-nine women, 32 with SUI I, 16 with SUI II, and 11 with SUI III were treated using an Er:YAG laser following the IncontiLase® protocol (Dynamis, Fotona, Slovenia). Therapy included five laser sessions with a 1-month interval between sessions. Objective (1-h pad test) and subjective data (International Consultation on Incontinence Questionnaire—Urinary Incontinence Short Form [ICIQ-UI SF], Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire [PISQ-12]) were assessed at baseline, after two and four laser sessions and 6 months and 2 years after the fifth laser session.

3. RESULTS SHOW IMPROVEMENT FOR SUI I AND SUI II

The results of this study show that objective cure/improve rates for mild SUI I were 69%, 78%, 91%, and 78% after two, four, and five laser sessions at the 6-month and 2-year follow-ups. Subjective cure rates (ICIQ-UI SF) also improved: 53%, 69%, 72%, and 66%, as well as sexual function (PISQ-12). For SUI II, objective cure/improve rates were 31%, 63%, 69%, and 50%, with a subjective cure rate of 13% at the 2-year follow-up. For SUI III, only one patient had an objective improvement after two and four laser sessions.

4. INCONTILASE® IS A SUSTAINABLE SOLUTION FOR MOST CASES OF SUI

Intravaginal laser therapy led to cure/improvement for SUI I and SUI II, but not for severe SUI III. The outcome was better after four to five laser sessions than after two laser sessions. Follow-up data 6 months and 2 years after the final laser intervention showed sustainability of the treatment.



One-hour pad test. Objective cure rates (%) are shown for patients with initial stress urinary incontinence (SUI) I, SUI II or SUI III at the following time points: 1 month after two laser sessions (2 M), 1 month after four laser sessions (4 M), and 6 months and 2 years after the fifth laser session (10 M and 28 M). Green – cured (pad weight ≤ 2 g), orange – improved (pad weight reduction of > 50% compared with baseline), red – not cured (pad weight reduction of ≤ 50% compared with baseline).

Authors: Kuszka A,

Gamper M, Walser C,

Kociszewski J, Viereck V

-

Published in: International

Urogynecology Journal, 2020



Non-ablative Er:YAG Laser for the Treatment of Type III Stress Urinary Incontinence (Intrinsic Sphincter Deficiency)

Authors: Gaspar A
& Brandi H

Published in: *Lasers in Medical Science*, 2017



1. NEW TREATMENT OPTION FOR TYPE III STRESS URINARY INCONTINENCE (SUI)

This pilot study aimed to determine the safety and efficacy of the IntimaLase® treatment for managing the symptoms of type III stress urinary incontinence (intrinsic sphincter deficiency) in women.

2. METHODOLOGY


Twenty-two patients having diagnosed ISD participated in the study and were treated with the laser (SP Spectro Dynamis, Fotona, Slovenia) throughout the whole length of the urethra through a specially designed cannula. Treatment consisted of two laser sessions with a 3-week interval in-between. Therapeutic efficacy was assessed by the ICIQ-SF questionnaire for determining incontinence severity and quality of life, and the 1-h pad test for objective measure. Patients were followed for 6 months.

3. VERY PROMISING RESULTS

According to the ICIQ-SF questionnaire, 64% of patients were cured and 18% had improved at 3 months post-treatment, while at 6 months 46% were cured and 23% had improved. No change in SUI stage was observed in 18% at 3 months and 32% at 6 months. Importantly, however, even those patients that saw no improvement in their SUI stage had a slight improvement in their absolute ICIQ-SF scores. Furthermore, according to the Pad test, clinical improvement was shown in 82% of patients at 3 months and in 50% of patients at 6 months after the treatment.

4. NON-ABLATIVE ER:YAG TECHNOLOGY SEEMS TO WORK ALSO FOR TYPE III SUI

This study suggests that IntimaLase® treatment is a safe and efficacious alternative for patients with type III stress urinary incontinence. Future controlled studies will confirm this data and evaluate the long-term effects.



Patient distribution (in %) based on SUI improvement rates at 3 and 6 months following intraurethral Er:YAG laser treatment.

Efficacy of Non-Ablative Vaginal Erbium Laser for rUTI Prevention in Postmenopausal Women

1. EVALUATING VAGINAL ER:YAG LASER FOR RECURRENT UTI PREVENTION

This study aimed to evaluate the effectiveness of non-ablative vaginal Er:YAG laser (VEL) in preventing recurrent urinary tract infections (rUTIs) in postmenopausal women. The objective was to determine whether VEL could serve as an alternative to local estrogen therapy (LET) by improving vaginal health, restoring microbiota balance, and reducing UTI recurrence.

2. RANDOMIZED CONTROLLED TRIAL COMPARING LASER AND ESTROGEN THERAPY

A prospective randomized controlled study included 80 postmenopausal women with a history of rUTI, divided into VEL (n=41) and LET (n=39) groups. The VEL group received three RenovaLase® laser sessions (SP Dynamis, Fotona, Slovenia) at 30-day intervals, while the LET group used vaginal estrogen for 12 weeks. Outcomes included number of UTI episodes, cure/improvement rates, vaginal pH, lactobacillus predominance, and Vaginal Health Index Score (VHIS). Follow-ups were conducted up to 6 months.

3. REDUCED UTI EPISODES AND IMPROVED VAGINAL HEALTH

Both treatments significantly reduced UTI recurrence compared to expected rates, with no significant difference between groups in cure or improvement rates. The VEL group demonstrated more sustained benefits, including fewer cumulative UTI episodes, higher long-term lactobacillus predominance, lower vaginal pH, and higher VHIS at 6 months. The treatment was well tolerated, with no serious adverse events reported, whereas some participants in the estrogen group discontinued due to local irritation.

4. LASER AS A PROMISING NON-HORMONAL ALTERNATIVE

Non-ablative vaginal erbium laser is a safe and effective option for preventing rUTIs in postmenopausal women, with results comparable to estrogen therapy and more durable improvements in vaginal health. It may be particularly valuable for patients who cannot use hormones, such as breast cancer survivors.

Authors: Zheng J, Li M, Chen Y, Zhang Z

Published in: *Lasers in Medical Science*, 2025



The primary outcome measures at 6 months follow up.

	Cumulative UTI episode number VEL Group (N = 30)	LET group (N = 31)
Predictive (without intervention)	60	62
Actual (with intervention)	14 Participant's outcome n (%)	18
	VEL Group (N = 30)	LET Group (N = 31)
Cured	16 (53.3)*	13 (41.9)
Improved	14 (46.7)**	18 (58.1)
No improvement	0	0

UTI, Urinary Tract Infection. VEL, Vaginal Erbium Laser; LET, Local Estrogen Therapy. The *P value when the "Cured" or "Improved" percentage of VEL compared with LET (* = 0.373, ** = 0.373, OR: 1.58, 95% CI: 0.58 to 4.35)

Hyaluronic Acid and Erbium Laser for the Treatment of Genitourinary Syndrome of Menopause

1. TESTING COMBINED LASER AND HA FOR GSM SYMPTOMS

This randomized pilot study aimed to evaluate whether adding vaginal hyaluronic acid (HA) to vaginal erbium laser (VEL) therapy improves treatment outcomes for genitourinary syndrome of menopause (GSM) in postmenopausal women. The focus was on reducing vaginal dryness and dyspareunia, common and distressing symptoms of GSM.

2. RANDOMIZED STUDY COMPARING LASER ALONE VS. LASER PLUS HA


A total of 100 sexually active postmenopausal women with GSM were randomized into three groups: (i) VEL alone (Group 1), (ii) VEL plus HA after each session (Group 2), and (iii) HA before and after each VEL session (Group 3). All participants received three laser treatments (SP Dynamis & XS Fotona Smooth, Fotona, Slovenia) at monthly intervals, and vaginal dryness and dyspareunia were assessed using visual analog scale (VAS) scores at baseline and during follow-up up to three months after treatment.

3. COMBINED HA AND LASER IMPROVED SYMPTOMS MORE EFFECTIVELY

All groups showed significant improvement in vaginal dryness and dyspareunia, but groups receiving additional HA (Groups 2 and 3) had greater and faster symptom relief than the laser-only group. Group 3, which used HA both before and after each laser session, showed the most substantial improvement in both outcomes, with statistically significant differences compared to the other groups. No serious adverse events occurred, and minor side effects were rare and self-limiting.

4. ADDING HA TO LASER BOOSTS GSM TREATMENT EFFECTIVENESS

The study suggests that vaginal HA enhances the effectiveness of vaginal erbium laser therapy in treating GSM, especially for relieving dryness and dyspareunia. Using HA both before and after laser sessions provided the best outcomes. This combination therapy may represent a more effective and patient-friendly approach for GSM.



Decrease in the visual analogue scale (VAS) score (mean ± 3SD) at 3 months after treatment.

Group 1: laser

Group 2: laser + HA

Group 3: HA + laser + HA

^ap < 0.01 versus Group 1. ^bp < 0.001 versus Group 1. ^cp < 0.05 versus Group 2

^dp < 0.01 versus Group 2

Authors: Fidecicchi T & Gambacciani M

Published in: Climacteric, 2024



A Novel Objective Evaluation Method, Shear Wave Elastography, in the Treatment of Atrophic Vaginitis by Nonablative Intravaginal Er:YAG Laser: A Randomized-Sham Controlled Pilot Study

Authors: Bayraktar E, Erel CT, Akturk H, Ozcivit Erkan IB, Hamid R, Alper E, Adaletli I, Urfalioglu M

Published in:
Menopause, 2024

1. EVALUATING LASER TREATMENT FOR POSTMENOPAUSAL ATROPHIC VAGINITIS

This study aimed to evaluate the effectiveness of intravaginal nonablative Er:YAG laser treatment for postmenopausal atrophic vaginitis using shear wave elastography (SWE) as a novel, objective assessment method. The goal was to determine whether Er:YAG laser therapy improves vaginal tissue elasticity and related clinical symptoms compared to a sham control.

2. DOUBLE-BLIND TRIAL USING LASER AND SHAM TREATMENTS

A randomized, double-blind, sham-controlled pilot study was conducted on 20 postmenopausal women diagnosed with atrophic vaginitis (12 in the laser group, 8 in the sham group). Participants underwent three laser (XS Dynamis, Fotona, Slovenia) or sham sessions at three-week intervals, and outcomes were measured using SWE to assess vaginal tissue elasticity, as well as vaginal pH, Vaginal Health Index (VHI), Female Sexual Function Index (FSFI), and Visual Analog Scale (VAS) for dyspareunia.

3. IMPROVED ELASTICITY, PH, PAIN, AND SEXUAL FUNCTION

The study found significant improvements in vaginal tissue elasticity (reduced stiffness) in the laser group compared to the sham group, as shown by SWE measurements. Additionally, participants in the laser group showed statistically significant improvements in vaginal pH, VHI, VAS scores, and FSFI scores, indicating better vaginal health and sexual function. Minor and transient side effects, such as slight discomfort and discharge, were noted but did not require treatment discontinuation.

4. LASER TREATMENT + SWE IS A PROMISING THERAPY

Intravaginal Er:YAG laser treatment appears to be an effective and safe option for improving vaginal tissue elasticity and alleviating symptoms of atrophic vaginitis in postmenopausal women. Shear wave elastography (SWE) presents a promising objective tool for evaluating intravaginal Er:YAG laser treatment efficacy.



The vaginal pH, VHI score, VAS score, and SWE (E_{mean}) and the improvement in the FSFI score following laser and sham applications.

		Laser treatment group (n = 12)	Sham control group (n = 8)	P ^a
		Mean ± SD	Mean ± SD	
Vaginal pH		5.1 ± 0.2	5.9 ± 0.4	<0.001 ^b
VHI score		17.4 ± 2.2	12.6 ± 1.0	<0.001 ^b
VAS score		2.1 ± 1.9	3.8 ± 3.6	0.04 ^b
FSFI score improvement		3.20 ± 3.31	0.10 ± 0.53	0.02 ^b
Anterior vaginal wall	SWE (baseline E_{mean})	27.9 ± 16.9	20.4 ± 3.9	0.27
	SWE (final E_{mean})	13.1 ± 6.3	20.0 ± 3.3	0.01 ^b
	P	0.002 ^c	0.48 ^c	
Posterior vaginal wall	SWE (baseline E_{mean})	15.7 ± 5.6	19.0 ± 11.4	0.52
	SWE (final E_{mean})	12.7 ± 10.2	19.4 ± 6.9	0.04 ^b
	P	0.05 ^c	0.58 ^c	

E, mean elasticity; FSFI, Female Sexual Function Index; SD, standard deviation; SWE, shear wave elastography; VAS, visual analog scale; VHI, Vaginal Health Index

^aMann-Whitney U test was performed

^bP<0.05: statistically significant

^cWilcoxon signed ranks test was performed

A Study of the Objective Benefits and Safety of Er:YAG Laser in the Treatment of Genitourinary Syndrome of Menopause

Authors: Avul Z & Guven CM

Published in: *Lasers in Medical Science, 2023*

1. EXAMINING THE EFFICACY AND SAFETY OF ER:YAG LASER FOR GSM TREATMENT

The aim of this study was to evaluate changes in vaginal pH and epithelium maturation after Er:YAG laser treatment, and to assess its safety and efficacy on the symptoms of genitourinary syndrome of menopause (GSM).

2. DATA USED FROM PATIENTS WHO OPTED FOR AN ESTROGEN FREE ALTERNATIVE

This was a retrospective study conducted between November 2019 and April 2022 that included 32 women diagnosed with GSM, with a mean age of 59.72 ± 5.66 years, who had not benefitted from lubrication treatment and could not or would not use estrogen. The patients had received three sessions of Er:YAG laser (SP Dynamis, Fotona, Slovenia). Vaginal maturation index (VMI), maturation value (MV) and vaginal pH values of the patients before and after laser treatment were compared.


3. GSM-RELATED SYMPTOMS DECREASED SIGNIFICANTLY

The study found a significant improvement in VMI, MV and vaginal pH at follow-up (5 months after treatment). After laser therapy, there was a significant decrease in vaginal pH ($p < 0.001$) and the proportion of parabasal cells in VMI ($p < 0.001$), while there was a significant increase in MV ($p < 0.001$) and the proportion of superficial cells in VMI ($p < 0.001$). In 84.4% of the patients, GSM-related symptoms regressed completely or decreased to a tolerable level.

4. ER:YAG LASER OFFERS AN EFFECTIVE TREATMENT ALTERNATIVE FOR GSM PATIENTS

Vaginal Er:YAG laser treatment offers a safe and effective alternative treatment method in a population of women with GSM who do not want to or cannot use estrogen therapy.





Vaginal pH and maturation value before and 5 months after laser treatment.

Sexual Function After Vaginal Er:YAG: The Results of a Large, Multicentric, Prospective Study

Authors: Gambacciani M,
Albertin E, Torelli MG,
Bracco GL, Casagrande AC,
Martella L, Baiocchi G,
Alfieri S, Russo N, Cervigni M

Published in:
Climacteric, 2020



OPEN  ACCESS



1. EXAMINING EFFECTS OF ER:YAG ON POSTMENOPAUSAL GSM

The aim of this multicentric, prospective study was to evaluate the effects of vaginal erbium laser (VEL-SMOOTH®) on sexual function in postmenopausal women suffering from genitourinary syndrome of menopause (GSM).

2. A LARGE, MULTICENTRIC STUDY OF 1081 POSTMENOPAUSAL WOMEN


The study was performed on an outpatient basis without anesthesia or drug use before or after the intervention, using an erbium laser (XS Fotona Smooth®) in 1081 postmenopausal women (age 54.3 ±3.9 years) treated with up to three laser applications every 30 days. Patients were assessed using the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R).

3. RESULTS SHOW IMPROVEMENT IN SEXUAL FUNCTION WITH NO SIDE EFFECTS

The FSDS-R scores significantly improved at all follow-ups ($p < 0.01$ vs. corresponding basal values, see Chart). Also individual FSFI domain scores significantly ($p < 0.01$, see Table) increased after VEL-SMOOTH® treatment, and remained significantly higher, up to the 24th week after the end of treatment. The total FSFI scores improved from basal values of 15.5 ± 1.5 to 27.0 ± 3.5 at the 24-week follow-up ($p < 0.01$). No adverse events were recorded during the study.

4. VEL-SMOOTH® IS AN EFFECTIVE SOLUTION FOR GSM IN POSTMENOPAUSAL WOMEN

The results of this large, multicentric, prospective study show that VEL-SMOOTH® is effective in improving sexual function and overall satisfaction with sexual life in postmenopausal women suffering from severe GSM.



The values of 554 Female Sexual Distress Scale-Revised (FSDS-R) tests in baseline conditions and after treatment with vaginal erbium laser (VEL).

* $p < 0.01$

After VEL treatment, 4, 12 in 24 weeks

The values of 569 Female Sexual Function Index (FSFI) tests in baseline conditions and after treatment with VEL.

FSFI domain	Before treatment	After treatment		
		4 weeks	12 weeks	24 weeks
Desire	3.0 ± 0.5	4.0 ± 1.5	4.0 ± 1.5	4.7 ± 1.5
Arousal	2.7 ± 1.5	4.0 ± 1.5	4.0 ± 1.5	4.0 ± 1.5
Lubrication	2.1 ± 0.5	4.8 ± 0.5	4.9 ± 0.5	4.8 ± 1.5
Orgasm	2.7 ± 0.7	4.0 ± 0.5	4.0 ± 0.5	4.0 ± 1.5
Satisfaction	2.5 ± 1.5	4.9 ± 1.5	4.9 ± 1.5	4.9 ± 1.5
Pain	2.5 ± 0.5	4.8 ± 0.5	4.9 ± 0.5	4.7 ± 1.5
Total score	15.5 ± 1.5	27.5 ± 2.5	27.6 ± 2.7	27.0 ± 3.5

Data are mean ± SE the values of each specific domain and total score after the treatment and at the end of the observation period were significantly ($p < 0.01$) different vs. corresponding basal values.

Histological Findings After Non-ablative Er:YAG Laser Therapy in Women with Severe Vaginal Atrophy

Authors: Gaspar A, Silva J, Calderon A, Di Placido V, Vizintin Z

Published in:
Climacteric, 2020



1. EVALUATING THE USE OF ER:YAG LASER FOR SEVERE VAGINAL ATROPHY

The aim of this study was to evaluate the effect of non-ablative erbium vaginal laser treatment on vaginal mucosa tissue affected by severe atrophy.

2. VAGINAL BIOPSIES PERFORMED BEFORE AND 3 MONTHS AFTER TREATMENT


Ten patients with severe genitourinary syndrome of menopause were treated with two sessions of the Er:YAG (XS Dynamis, Fotona, Slovenia) separated by 4 weeks. Vaginal biopsies were performed before and 3 months after the second treatment. The improvement in vaginal atrophy was assessed using multiple measuring tools before and 6 months after the treatment. The degree of patient's satisfaction was also assessed.

3. RESULTS SHOW SIGNIFICANT IMPROVEMENT IN VAGINAL WALL MUCOSA

Microscopic examination showed significant changes in the main structural components of the vaginal wall mucosa after two non-ablative Er:YAG laser sessions. The epithelial thickness increased from 45 μm (10-106 μm) to 153 μm (97-244 μm) measured 3 months after the final laser treatment. Vaginal atrophy improved in all patients by all measured outcomes. The degree of patient satisfaction was very high (3.6 on the Likert four-point scale). No adverse events or complications were observed in any of the sessions.

4. ER:YAG LASER IS A SAFE AND EFFECTIVE TREATMENT FOR SEVERE VAGINAL ATROPHY

The non-ablative Er:YAG laser seems to be a safe and effective method to increase epithelial thickness of the vaginal mucosa in patients with severe vaginal atrophy.



40x magnification shows an average epithelial thickness before the treatment (left picture) of 106 μm (85-120 μm) with an average of 9 (7-11) layers of cells and no glycogenic load, and after the treatment (right picture) 183 μm (160-215 μm) average of epithelial thickness with an average of 21 (15-25) layers of cells, with a significant amount of glycogen and basal cell hyperplasia.

Thickness of endometrial epithelium	Before laser treatment	3 months after final laser treatment
Epithelial thickness (μm)	45.0 $\pm$ 33.4	152.9 $\pm$ 44.7
Number of cell layers	6.9 $\pm$ 2.4	18.9 $\pm$ 5.6

Long-term Effects of Vaginal Er:YAG Laser in the Treatment of Genitourinary Syndrome of Menopause

1. TWO-YEAR FOLLOW-UP OF PATIENTS

First longitudinal study on the use of minimally invasive Er:YAG technology for the treatment of genitourinary syndrome of menopause (GSM), showing long-term efficacy of RenovaLase® (Dynamis, Fotona, Slovenia).

2. LARGE GROUP OF TREATED PATIENTS

205 postmenopausal women received three laser sessions of RenovaLase® at 30-day intervals. Study assessment was performed throughout the 24-month follow-up period and included the subjective visual analogue scale (VAS) and the objective vaginal health index score (VHIS). Furthermore, postmenopausal women suffering from stress urinary incontinence symptoms were evaluated with the International Consultation on Incontinence Questionnaire—Urinary Incontinence Short Form (ICIQ-UI SF).

3. BETTER RESULTS COMPARED TO LOCAL TREATMENT

Non-ablative Er:YAG laser treatment induced a statistically significant ($p < 0.01$) decrease in VAS for vaginal dryness and dyspareunia, and VHIS was significantly increased ($p < 0.01$) up to the 12th month after the final laser treatment. Values reported after 18 and 24 months returned to the baseline level. Furthermore, 144 women suffering from mild to moderate SUI also showed improvement in urine leakage. No major adverse events were reported.

4. STRONG PROOF OF EFFICACY AND SAFETY OF THE RENOVALASE® TREATMENT

The efficacy of non-ablative Er:YAG laser treatment has been demonstrated by several clinical studies, but data on long-term effects was lacking to fully support it. This longitudinal study therefore fills an important gap in the story of non-invasive treatments for GSM.

Authors: Gambacciani M,

Levancini M, Russo E, Vacca L,

Simoncini T, Cervigni M

Published in:

Climacteric, 2018



OPEN  ACCESS



Intraurethral Er:YAG Laser for the Management of Urinary Symptoms of Genitourinary Syndrome of Menopause: A Pilot Study

Authors: Gaspar A, Maestri S,
Silva J, Brandi H, Luque D,
Koron N, Vizintin Z

-

Published in: *Lasers in Surgery
and Medicine*, 2018



OPEN ACCESS



1. ASSESSING THE SAFETY AND EFFICACY OF INTRAURETHRAL ER:YAG TREATMENT

There are several treatment methods available for the management of VVA symptoms of GSM, whereas urinary tract dysfunction often remains overlooked and undertreated. The objective of this pilot study was to assess the safety and efficacy of intraurethral Er:YAG laser treatment of urinary symptoms of GSM.

2. TWO ER:YAG SMOOTH™ MODE TREATMENTS

29 female patients, aged between 56 and 77 years, with diagnosed GSM, having less than 5% of vaginal superficial cells in the cytology, vaginal pH higher than 5, with urinary symptoms of GSM (dysuria, frequency, urgency) and impaired continence due to urethral atrophy, received two sessions of the intraurethral non-ablative Er:YAG SMOOTH™ mode laser therapy (SP Spectro Dynamis, Fotona, Slovenia), with a 3-week interval in-between the sessions. The therapeutic efficacy was determined using ICIQ-SF, the 1-hour pad test and VAS scores. Follow-ups (FU) were at 3 and 6 months.

3. ALL URINARY SYMPTOMS OF GSM IMPROVED

The intraurethral laser procedure performed in this study successfully reduced the symptoms of dysuria, urgency, and frequency in the treated patients. A statistically significant long-term effect was observed, and the positive effects appear to last up to 6 months following laser treatment.

4. AN EFFICIENT, SAFE AND RELIABLE TREATMENT ALTERNATIVE

Non-ablative Erbium SMOOTH™ mode therapy proves to be a valid and reliable alternative to traditional treatment options, as its positive effects last up to 6 months, and based on the modality, both VVA and urinary symptoms can be addressed. Most importantly, Erbium SMOOTH™ laser treatment can be used in patient populations for which other treatment methods are not recommended (e.g. breast cancer survivors).

*Average improvement rates (%) from baseline values.
Results are presented as mean (SD).*

	3-month FU	6-month FU
Dysuria	87 (12)	64 (25)
Urgency	79 (18)	44 (35)
Frequency	77 (18)	52 (23)
ICIQ-UI	64 (25)	40 (31)
1-h pad test (g)	59 (13)	42 (20)

Vaginal Er:YAG Laser as Second-generation Thermotherapy for the Genitourinary Syndrome of Menopause: A Pilot Study in Breast Cancer Survivors

1. A MINIMALLY INVASIVE SOLUTION FOR BREAST CANCER SURVIVORS

The objective of the study was to evaluate the efficacy and acceptability of the RenovaLase® procedure for treating patients with premature GSM due to estrogen blocking therapy.

2. METHODOLOGY

Forty-three postmenopausal breast cancer survivors received 3 RenovaLase® treatments (XS Dynamis, Fotona, Slovenia) with 30 days in-between the sessions. Symptoms were evaluated before the treatment and after 1, 3, 6, 12, and 18 months using two methods: subjective Visual Analog Scale (VAS) and objective Vaginal Health Index Score (VHIS).

3. VERY PROMISING RESULTS


VAS values for vaginal dryness showed a statistically significant reduction from baseline 8.5 ± 1.0 cm to 4.4 ± 1.2 cm after 3 months, to 5.5 ± 1.5 cm after 12 months, and returned to nearly baseline levels at 18 months (NS vs basal values). VAS values for dyspareunia followed a similar pattern. VHIS score showed a statistically significant increase from baseline values of 8.1 ± 1.3 to 21.0 ± 1.4 after the third treatment and to 18 ± 1.8 at twelve months from the final laser treatment. VHIS score was kept above baseline values even after 18 months from the final treatment (NS vs basal values).

4. RENOVALASE IS A SAFE TREATMENT FOR BREAST CANCER SURVIVORS

Results from this study indicate that RenovaLase® is a treatment option for GSM in breast cancer patients whose current treatment options are still very limited.

Authors: Gambacciani M
& Levancini M

Published in:
Menopause, 2017



Effect of VEL on dyspareunia in postmenopausal breast cancer survivors.

RenovaLase® Treatment Induces Significant Improvement of Genitourinary Syndrome of Menopause (GSM)

Authors: Gambacciani M,
Levancini M, Cervigni M

Published in:
Climacteric, 2015

1. HIGH IMPACT JOURNAL

Published in *Climacteric*, the Journal of the International Menopause Society (IMS). The journal was founded in 1998 and has become a leader in publishing peer-reviewed research on menopause.

2. HORMONE-FREE TREATMENT FOR THE SYMPTOMS OF GENITOURINARY SYNDROME OF MENOPAUSE (GSM)


GSM (or vulvovaginal atrophy) is a chronic condition, which affects up to half of all postmenopausal women. Symptoms of GSM include dryness, burning, irritation, lack of lubrication and impaired sexual function. Traditional treatments have been limited to local or systemic estrogen therapy.

3. MATERIALS AND METHODS

45 postmenopausal women with symptoms of GSM were treated with a non-ablative vaginal erbium laser (XS Dynamis, Fotona, Slovenia). As a control group, 25 postmenopausal women were treated with an established treatment for GSM (1 g of vaginal gel containing 50 µg of estriol twice weekly, for 3 months).

4. SIGNIFICANT IMPROVEMENT OF VAGINAL DRYNESS AND DYSpareunia

RenovaLase® treatment resulted in a rapid and long-lasting improvement in the signs and symptoms of GSM. This treatment is of special importance in the treatment of postmenopausal women who cannot be treated with hormones.



Effect of RenovaLase® therapy on dyspareunia using the visual analog score (VAS) on a 10-point scale for the women receiving laser treatment and the women receiving estriol. In the estriol group, a reduction of efficacy can be seen 12 weeks after the end of treatment. Conversely, the RenovaLase® group maintained the same positive results throughout the entire study period up to the 6-month follow-up.

Treating Vaginal Laxity Using Non-ablative Er:YAG Laser: A Retrospective Case Series of Patients From 2.5 Years of Clinical Practice

1. A MINIMALLY INVASIVE TREATMENT FOR VAGINAL LAXITY

The aim of this study was to retrospectively assess the effectiveness and safety of a nonablative Er:YAG laser procedure (IntimaLase®, XS Dynamis, Fotona, Slovenia). for vaginal laxity in patients treated in a clinical practice during a 2.5-year period.

2. A REVIEW OF 2.5 YEARS OF CLINICAL PRACTICE

Laser treatment for vaginal laxity was performed using an intravaginal nonablative Er:YAG laser. Effectiveness was assessed using a Patient Satisfaction Questionnaire and also by independent evaluation of before and after treatment photographs of the patients' introitus. The safety and tolerability of the procedure was monitored in all patients.

3. RESULTS SHOW IMPROVEMENT IN PATIENTS' VAGINAL TIGHTNESS SATISFACTION

The study showed an improvement of sexual gratification and improvement of vaginal tightness, as assessed by patients. The tightness of the introitus was also improved, as assessed by independent evaluators. 92.7% of patients experienced improvement of sexual gratification after the IntimaLase® laser treatment. The results of the visual evaluation of the grade of laxity improvement in the introitus area, when open introitus photos were evaluated, showed that 69% (n = 20/29) of patients had an improvement of laxity.

4. ER:YAG LASER PROVIDES IMPROVEMENT OF SEXUAL SENSATION

The results of this study have confirmed that patients suffering from vaginal laxity can be effectively treated using the nonablative Er:YAG IntimaLase® procedure without adverse effects.

Authors: Mitsuyuki M, Stok U, Hreljac I, Yoda K, Vizintin Z

Published in:
Sexual Medicine, 2020



OPEN  ACCESS



The Efficacy of Er:YAG Laser in the Treatment of Decreased Sexual Sensation: A Randomized, Placebo-controlled Trial

Authors: Sathaworawong A, Manuskiatti W, Phatihattakorn C, Ungaksornpairote C, Ng JN
-
Published in: *Lasers in Medical Science*, 2021

1. EXAMINING EFFECTS OF SUI SEVERITY AND NUMBER OF LASER INTERVENTIONS

The study is believed to be the first randomized, placebo-controlled trial comparing the efficacy and safety of Er:YAG laser (XS Dynamis, Fotona, Slovenia) in treating decreased sexual sensation. Vaginal laxity, a common cause of decreased sexual sensation, is a common problem affecting the quality of life of women worldwide.

2. THREE STAGES OF SUI TREATED WITH THE INCONTILASE® PROTOCOL

Forty-two patients with decreased sexual sensation were randomized into 2 groups: intervention (laser treatment) and control (placebo treatment). Both groups received two treatments, at 1-month interval. Subjective and objective evaluations were done at baseline, 1-, 3-, and 6-month follow-ups. Pain score and adverse effects were also recorded.

3. RESULTS SHOW IMPROVEMENT IN PATIENTS' VAGINAL TIGHTNESS SATISFACTION

In the laser group, there was significant improvement in the patients' vaginal tightness satisfaction at 1- and 3-month follow-ups ($P = 0.002$ and 0.004) and also in the patients' overall satisfaction at 1- and 3-month follow-ups ($P = 0.003$ and 0.001). Pelvic floor muscle contraction was significantly better in the laser group after the first treatment ($P = 0.043$). No serious adverse effects were noted.

4. ER:YAG LASER PROVIDES IMPROVEMENT OF SEXUAL SENSATION

The results of the study show that Er:YAG laser provides improvement of sexual sensation for an average of 3 months following 2 monthly treatments.



Patients' vaginal tightness satisfaction on all follow-up visits.

	1-month follow-up n (%)	3-month follow-up n (%)	6-month follow-up n (%)
Laser group			
Worst	0 (0.0)	0 (0.0)	1 (5.0)
No change	1 (4.8)	1 (5.3)	6 (30.0)
Slightly improved	6 (28.6)	6 (31.6)	2 (10.0)
Moderately improved	7 (33.3)	8 (42.1)	6 (30.0)
Significantly improved	7 (33.3)	4 (21.1)	5 (25.0)
Placebo group			
Worst	0 (0.0)	0 (0.0)	0 (0.0)
No change	4 (19.0)	7 (33.3)	7 (33.3)
Slightly improved	11 (52.4)	8 (38.1)	7 (33.3)
Moderately improved	6 (28.6)	6 (28.6)	6 (28.6)
Significantly improved	0 (0.0)	0 (0.0)	1 (4.8)
P value	0.002*	0.004*	0.318

*Statistically significant difference

Effect of Er:YAG Laser on Pelvic Floor Strength and Sexual Satisfaction in Women Complaining of Vaginal Looseness: A Randomized Controlled Trial

Authors: Ahmed SM, Kotb HG, Yousef AM, Ahmed H

Published in: Polish Journal of Physiotherapy, 2019



1. EXAMINING THE EFFECTIVENESS OF ER:YAG LASER FOR TREATING VAGINAL LOOSENESS

The study aimed to determine the effect of Er:YAG laser on pelvic floor strength as well as sexual satisfaction in women complaining of vaginal looseness.

2. A PROSPECTIVE, SINGLE-BLIND, RANDOMIZED CONTROLLED TRIAL WITH 30 PATIENTS

Thirty women complaining of vaginal looseness with a decrease in pelvic floor strength and sexual satisfaction, aged 40–50 years, were randomized into 2 equal groups. Group (A) received pelvic floor training exercise (kegel exercise) for 8 weeks, while group (B) received Er:YAG laser (Dynamis, Fotona, Slovenia) in addition to kegel exercise for 8 weeks. All women in both groups were evaluated before starting the study, after 4 weeks and after 8 weeks of the treatment with a Peritron device to assess pelvic floor strength and with the Millheiser sexual satisfaction scale to assess sexual satisfaction.

3. RESULTS SHOW IMPROVEMENT IN PELVIC FLOOR STRENGTH AND SEXUAL SATISFACTION

There was a highly significant increase in pelvic floor strength and sexual satisfaction at post 8 weeks and post 4 weeks of treatment, in favor of group (B) ($P = 0.0001$).

4. ER:YAG LASER THERAPY IS AN EFFECTIVE OPTION FOR TREATING VAGINAL LOOSENESS

Er:YAG laser represents an effective, safe and successful therapy adjunct to kegel exercise in treating vaginal looseness in women.

Pelvic floor muscle strength at different measuring periods for both groups.

Pelvic floor muscle strength	Pre treatment (Mean $\pm$ SD)	Post 4 weeks of treatment (Mean $\pm$ SD)	Post 8 weeks of treatment (Mean $\pm$ SD)
Group A	58.86 $\pm$ 4.27	69.33 $\pm$ 3.84	80.33 $\pm$ 3.75
Group B	58.86 $\pm$ 4.27	75.4 $\pm$ 4.06	88.13 $\pm$ 2.32
<i>Within groups (Pre vs. Post) Multiple pairwise comparison (Post hoc tests) among different measuring periods for Pelvic floor muscle strength at both groups</i>			
p-value	Pre Vs. Post 4 weeks of treatment	Pre Vs. Post 8 weeks of treatment	Post 4 weeks of treatment Vs. 8 weeks of treatment
Group A	0.0001 ^{HS}	0.0001 ^{HS}	0.0001 ^{HS}
Group B	0.0001 ^{HS}	0.0001 ^{HS}	0.0001 ^{HS}
<i>Multiple pairwise comparison tests (Post hoc tests) for the Pelvic floor muscle strength between both groups at different measuring periods</i>			
Group A Vs. group B	Pre treatment	Post 4 weeks of treatment	Post 8 weeks of treatment
P-value	1.00 ^{NS}	0.0001 ^{HS}	0.0001 ^{HS}

^{NS} P > 0.05 = Non-significant, ^{HS} P < 0.01 = highly significant, P = Probability

Sexual satisfaction grades at different measuring periods for both groups.

Friedman test for sexual satisfaction grades						
	Group A				Group B	
	X2-value		21.535		30	
	p-value		0.0001 ^{HS}		0.0001 ^{HS}	
Wilcoxon Signed Rank tests (within groups)						
	Pre Vs. Post 4 weeks of treatment		Pre Vs. Post 8 weeks of treatment		Post 4 weeks of treatment Vs. post 8 weeks of treatment	
	Z-value	p-value	Z-value	p-value	Z-value	p-value
Group A	-2.828	0.005 ^{HS}	-3.638	0.0001 ^{HS}	-2.646	0.008 ^{HS}
Group B	-3.508	0.0001 ^{HS}	-3.453	0.001 ^{HS}	-3.52	0.0001 ^{HS}
Mann-Whitney tests between groups						
Group A Vs. group B	Pre treatment		Post 4 weeks of treatment		Post 8 weeks of treatment	
U-value	71.5		15		0.00	
Z-value	-1.818		-4.229		-5.06	
p-value	0.069 ^{NS}		0.0001 ^{HS}		0.0001 ^{HS}	

^{NS} P > 0.05 = Non-significant, ^{HS} P < 0.01 = highly significant, P = Probability

Up to 3-year Follow-up of Patients with Vaginal Relaxation Syndrome Participating in Laser Vaginal Tightening

Authors: Gaviria PJE,
Korosec B, Fernandez J,
Montero G

Published in: *Journal of the Laser and Health Academy*, 2016



OPEN ACCESS



1. MINIMALLY INVASIVE APPROACH TO SIGNIFICANTLY IMPROVE WOMEN'S QOL

Non-surgical treatments that promote perineal muscle strength and certain pharmacological agents are very safe, but offer limited efficacy. On the contrary, surgical interventions offer high efficacy but are at the same time associated with a high risk of nerve damage and therefore loss of sensation. The gap between both extremes has been filled with the IntimaLase® treatment, which offers minimal invasiveness but high efficacy.

2. A 3-YEAR FOLLOW-UP TO PROVE INTIMALASE® EFFICACY


Several other clinical studies have shown a positive effect of the laser treatment on vaginal tightness, however, data on the long-term effectiveness was missing. 60 patients received 1-4 laser sessions of IntimaLase® (XS Dynamis, Fotona, Slovenia) at 15 to 30-day intervals. Study assessment was performed throughout the 36 months and included laser vaginal tightening (LVT) questionnaires and self-assessment reports.

3. GREAT RESULTS

Patients reported the average duration of effect from the treatment was 16 months, with significant improvement of stress urinary incontinence and prolapse. No serious adverse effects were reported. Furthermore, data showed that 58% of patients were extremely satisfied or very satisfied with the treatment and 83.3% of participants would be willing to repeat the therapy.

4. INTIMALASE® TECHNOLOGY AS AN ALTERNATIVE FOR UNCOMFORTABLE, HIGH-RISK SURGICAL PROCEDURES

Because of its minimal invasiveness and positive results, a vast majority of patients finds the principle of IntimaLase® therapy very appealing. Longitudinal studies are bringing more evidence to the field and hopefully more women will stand a chance to undergo the laser treatment first before considering surgical intervention.



The duration of improvement after laser therapy.

Vaginal Erbium Laser Versus Pelvic Floor Exercises for the Treatment of Pelvic Organ Prolapse: A Randomised Controlled Trial

1. COMPARING LASER VS. EXERCISES FOR PROLAPSE SYMPTOM RELIEF

This randomized controlled trial aimed to compare the effectiveness of vaginal erbium:YAG (Er:YAG) laser treatment with pelvic floor exercises (PFE) for improving symptoms of mild to moderate pelvic organ prolapse (POP). The goal was to assess if laser therapy is a viable alternative to standard conservative treatment using PFE, with a focus on patient-reported outcomes and safety over a 24-month period.

2. RANDOMIZED TRIAL COMPARING LASER AND PELVIC FLOOR EXERCISES

61 patients with grade II-IV cystoceles were treated (Dynamis, Fotona, Slovenia) 2-5 times at 2-month intervals. Prolapses were photographed and graded using the Barden-Walker scale.

3. LASER AND EXERCISES BOTH REDUCED SYMPTOMS

Both laser and PFE groups showed similar improvements in POPDI-6 scores at 4 months, confirming non-inferiority of laser to PFE. Approximately 65% of laser participants and 61% of PFE participants reported subjective improvement. By 24 months, around half of women in both groups sought additional, yet conservative treatment. No serious adverse events were reported.

4. LASER EQUALS EXERCISES IN SYMPTOM IMPROVEMENT

Vaginal erbium laser therapy and pelvic floor exercises offer comparable short-term symptom improvement for women with mild to moderate prolapse.

Authors: Page A-S, Borowski E, Bauters E, Housmans S, Van der Aa F, Deprest J

Published in: European Journal of Obstetrics and Gynecology, 2024



Non-Ablative Vaginal Er:YAG Laser Treatment of Patients with Cystocele and Stress Urinary Incontinence – a Retrospective Study

Authors: Novakov Mikic A ,
Lepes Bingold B, Hreljac I,
Vizintin Z
-
Published in: *European
Gynecology and Obstetrics*,
2023

1. EVALUATING SMOOTH® MODE ON PATIENTS WITH PELVIC ORGAN PROLAPSE & SUI

The study evaluated the efficacy of erbium laser treatment (VEL) using the non-ablative SMOOTH® mode procedure ProlapLase® (Fotona, Slovenia) on patients with pelvic organ prolapse (cystocele) and co-existing stress urinary incontinence (SUI).

2. A RETROSPECTIVE STUDY OF DATA RECORDED DURING A TWO-YEAR PERIOD

The study carried out by the analysis of data recorded during a two-year period from charts of 41 patients that completed VEL treatment for cystocele (Group A); 27 of these also had concomitant stress urinary incontinence (Group B). The average cystocele grade in Group A was 2, while in Group B it was 1.96.

3. CLINICALLY SIGNIFICANT IMPROVEMENT IN SYMPTOMS NOTED


The results showed that patients experienced a decrease in cystocele grade by an average of 0.95 after undergoing an average of 2.7 laser sessions. Among patients with both cystocele and SUI, there was a clinically significant improvement in SUI symptoms following the VEL treatment. The average ICIQ-UI short form score decreased from 11.33 at baseline to 3.56 after completing the treatment sessions.

4. ER:YAG SMOOTH® MODE TREATMENT IS AN EFFECTIVE AND SAFE OPTION

The study reported high patient satisfaction with the treatment results, indicating that vaginal non-ablative Er:YAG laser treatment using the SMOOTH® mode was well-received by the patients who underwent the procedure.



OPEN ACCESS



The effect of intravaginal non-ablative Er:YAG treatment on cystocele grade distribution (0-4).

Non-ablative Vaginal Er:YAG Laser for the Treatment of Cystocele

1. NEW MINIMALLY INVASIVE OPTION

The principle of non-ablative Er:YAG laser has been widely adopted for treating various conditions associated with pelvic floor dysfunction. Lately it has also been used to treat pelvic organ prolapse (POP). Since surgical treatments often come with the cost of long downtime and a high possibility of adverse events, developing alternative minimally invasive treatments is of a great importance.

2. METHODOLOGY

61 patients with grade II-IV cystoceles were treated (Dynamis, Fotona, Slovenia) 2-5 times at 2-month intervals. Prolapses were photographed and graded using the Barden-Walker scale.

3. EXCELLENT RESULTS


95% of the patients showed a reduction of at least one grade, 85% of which had achieved grade 0 or I, and 15% achieved grade II. 90% of the patients were very satisfied or satisfied with the treatment. No major adverse effects were noted.

4. PROLAPLASE® IS A BREAKTHROUGH, MINIMALLY INVASIVE OPTION FOR PATIENTS WITH POP

Clinical research supports the efficacy of the ProlapLase® treatment. With additional studies this innovative procedure may become a well-recognized minimally invasive alternative to surgery.

Authors: Bizjak Ogrinc U
& Sencar S

Published in: Italian Journal
of Gynaecology and
Obstetrics, 2017



The effect of ProlapLase® on
cystocele grade distribution at
baseline and follow-ups.



Nd:YAG/Er:YAG Dual Laser Compared with Topical Steroid to Treat Vulvar Lichen Sclerosus: A Randomised Controlled Trial

Authors: Zivanovic I, Gamper M, Fesslmeier D, Walser C, Regauer S, Viereck V

Published in: BJOG:

An International Journal of Obstetrics and Gynaecology, 2023



1. COMPARING DUAL ND:YAG/ER:YAG LASER TREATMENT WITH CORTICOSTEROID THERAPY

The aim of this randomised controlled trial was to evaluate the efficacy and safety of a novel non-ablative Nd:YAG/Er:YAG dual laser treatment for vulvar lichen sclerosis (LS) in comparison with the recommended first-line therapy with topical steroid.

2. CHANGES MEASURED IN OBJECTIVE VALIDATED CLINICAL LS SCORE

44 women were included in the laser group and 22 in the steroid group. Patients in the laser group received four laser treatments with a dual Nd:YAG/Er:YAG laser (SP Spectro Dynamis, Fotona, Slovenia), at baseline and after 1, 2 and 4 months. The comparison group received standardised topical steroid for 6 months. The primary outcome was the change in objective clinical LS score in the laser arm between baseline and 6 months. Secondary outcomes were changes in subjective and objective measures between baseline and 6-month follow-up, safety of the laser treatment and comparisons between laser and steroid outcomes.

3. LASER TREATMENT WAS EFFECTIVE, SAFE AND WELL TOLERATED

The total LS score decreased by -2.34 ± 1.20 (95% CI -2.71 to -1.98) in women treated with laser compared with a decrease of -0.95 ± 0.90 (95% CI -1.35 to -0.56) in those receiving steroid applications ($p < 0.001$). Subjective severity scores (on visual analogue scale) and vulvovaginal symptoms questionnaire scores improved similarly for the laser and steroid arms without significant differences between the two treatments. Patient satisfaction was higher in the laser arm than in the steroid arm ($p = 0.035$).

4. LASER IS A PROMISING ALTERNATIVE TO CORTICOSTEROID THERAPY

Non-ablative dual Nd:YAG/Er:YAG laser therapy was safe and significantly improved clinical outcomes and subjective symptoms at the 6-month follow-up. This suggests that laser may be a promising alternative to corticosteroid therapy.

Improvement of lichen sclerosis (LS) score, VAS symptoms and VSQ at six months follow-up.

Variable	Baseline, mean $\pm$ SD	Six months, mean $\pm$ SD	Change, mean $\pm$ SD	p value, within
LS score total				
Laser (n = 44) ^a	6.27 $\pm$ 1.25	3.93 $\pm$ 1.34	-2.34 $\pm$ 1.20	<0.001
Steroid (n = 22)	6.05 $\pm$ 1.50	5.09 $\pm$ 1.15	-0.95 $\pm$ 0.90	0.014
p value between	0.397	<0.001	<0.001	
VAS total (itching, burning, pain)				
Laser (n = 44) ^a	11.59 $\pm$ 6.87	5.75 $\pm$ 6.50	-5.84 $\pm$ 6.19	<0.001
Steroid (n = 22)	9.36 $\pm$ 5.60	4.00 $\pm$ 3.12	-5.36 $\pm$ 6.33	0.001
p value between	0.303	0.647	0.881	
VAS total (Q1-16)				
Laser (n = 44) ^a	8.11 $\pm$ 3.58	4.89 $\pm$ 4.42	-3.23 $\pm$ 3.21	<0.001
Steroid (n = 22)	7.68 $\pm$ 3.20	5.36 $\pm$ 4.27	-2.32 $\pm$ 3.43	0.043
p value between	0.473	0.637	0.408	

Efficacy of Non-ablative Laser Therapy for Lichen Sclerosus: A Randomized Controlled Trial

1. COMPARING THE EFFECTS OF LASER TO TOPICAL CORTICOSTEROID TREATMENT

A total of 40 patients were included in the study and were randomized into the active group (combined treatment with topical corticosteroids and laser) or control group, who received treatment with topical corticosteroids only.

The patients in the active group received three Nd:YAG laser treatments (SP Spectro Dynamis, Fotona, Slovenia) every 14 days. One week before the first laser treatment, the patients in this group started pre-treatment with topical corticosteroid betamethasone (Diprosone) to alleviate symptoms and increase treatment comfort. This therapy lasted 3 weeks with decreasing dosage: twice daily during the first week, once daily during the second week, and every second day during the third week.

The control group received the topical corticosteroid betamethasone (Diprosone) for 4 weeks with decreasing dose: twice daily during the first 2 weeks, once daily during the third week, and every second day during the fourth week.

2. THE EFFECTS ARE HISTOLOGICALLY PROVEN

The thickness of sclerosis was reduced significantly after the combined treatment, but not after the corticosteroid treatment.

3. IMPROVEMENT HAS BEEN MEASURED OBJECTIVELY AND SUBJECTIVELY

Both the combined and corticosteroid treatments reduced the intensity of symptoms (itching, burning, pain) compared with the baseline, however, the reduction was statistically significantly better in the active group for all symptoms. The effect of LS on the quality of the patient's sex life was significantly reduced only in the active group.

4. ADDITIONAL ADVANTAGES OF LASER TREATMENT

Most patients have a negative attitude towards the long-term use of topical corticosteroids, so they seek better and more permanent solutions. Initial results regarding laser therapy appear promising not only due to its efficacy, but also its ease of use, as patients do not need to apply their medicine on a daily basis.

Authors: Bizjak Ogrinc U,
Sencar S, Luzar B,
Lukanovic A

Published in: *Journal of Obstetrics and Gynaecology Canada*, 2019



Efficacy of Two Laser Treatment Strategies for Breast Cancer Survivors with Genitourinary Syndrome of Menopause

Authors: Okui NP,
Okui M, Kouno Y, Nakano K,
Gambacciani M

Published in: Cereus, 2023



1. EVALUATING VEL VS. VEL+ND:YAG FOR PAIN IN BREAST CANCER SURVIVORS WITH GSM

The aim of this study was to compare the effectiveness of vaginal Er:YAG SMOOTH mode laser (VEL) treatment with a combined Nd:YAG laser + VEL treatment (Fotona, Slovenia) over time, with respect to therapeutic targets for pain in breast cancer survivors with GSM.

2. MORE THAN 200 WOMEN WHO RECEIVED EITHER VEL OR VEL+ND:YAG WERE ENROLLED

This retrospective, case-control study targeted sexually active breast cancer survivors who reported GSM with vulvodynia and dyspareunia. Propensity score (PS)-matching analysis was used to compare two-year postoperative data retrospectively. Symptoms were assessed using the visual analog scale (VAS) for vulvodynia before and after laser treatment for one, three, six, 12, and 24 months after completion. Female Sexual Function Index (FSFI) and Vaginal Health Index Score (VHIS) were also assessed.

3. RESULTS SHOW GREATER IMPROVEMENT FROM COMBINED TREATMENT

Comparing the two groups, the results confirmed that VEL+Nd:YAG treatment of the vaginal vestibule and vaginal opening reduced superficial vulvar pain more effectively, extensively, and over a longer period than VEL. FSFI improved significantly in the VEL+Nd:YAG group and persisted for two years. VHIS improved equally in both groups and was not significantly different. The VAS values in the VEL+Nd:YAG group and the VEL group decreased from the pre-treatment to 3.79 ± 0.63 ($p < 0.001$ vs. baseline) and 5.56 ± 0.89 ($p < 0.001$ vs. baseline) after the third treatments, respectively. After 24 months, the VAS value in the VEL+Nd:YAG group and the VEL group was at 4.43 ± 1.38 ($p < 0.001$ vs. baseline) and 5.56 ± 0.89 ($p < 0.001$ vs. baseline), respectively.

4. AN EFFECTIVE NOVEL TREATMENT FOR BREAST CANCER SURVIVORS WITH GSM

The study showed that VEL and Nd:YAG combination treatment is effective as a novel treatment for GSM with superficial vulvar pain and dyspareunia in breast cancer survivors. Over two years, the combination treatment was more effective than VEL alone. Combination therapy had no significant adverse events.

Laser Treatment for Patients With Vulvodynia and Interstitial Cystitis/Bladder Pain Syndrome: A Case Series (The UNICORN-3 Study)

1. EXPLORING LASER THERAPY FOR IC/BPS AND VULVODYNIA

This study aimed to assess the effectiveness of combined vaginal erbium:YAG (VEL) and neodymium:YAG (Nd:YAG) laser treatments in women suffering from interstitial cystitis/bladder pain syndrome (IC/BPS) and vulvodynia. The goal was to determine if addressing both vaginal and vulvar tissues could alleviate symptoms that had not responded to conventional therapies.

2. CASE SERIES USING COMBINED VAGINAL AND VULVAR LASER TREATMENT

Fifteen women diagnosed with both IC/BPS and vulvodynia underwent three combined VEL + Nd:YAG laser sessions (SP Dynamis, Fotona, Slovenia) at one-month intervals. Clinical outcomes were assessed using pain scores (NRS-11), vulvodynia tests, bladder symptom indices (ICSI/ICPI), pelvic pain/urgency/frequency scores (PUF), and urination diaries. Follow-ups were conducted at 6 and 12 months to evaluate short- and long-term effects.

3. LASER REDUCED PAIN, URGENCY, AND FREQUENCY SIGNIFICANTLY



Significant improvements were observed in vulvodynia test scores, bladder pain (NRS-11), ICSI, ICPI, PUF scores, mean urination volume, and frequency, all showing sustained benefits at both six and 12 months.

4. COMBINED LASER EFFECTIVE, SUGGESTING SYNERGISTIC SHORT-TERM RELIEF

The combined VEL + Nd:YAG laser treatment appears effective for managing coexisting IC/BPS and vulvodynia, offering both genital and urinary symptom relief.

Authors: Okui N, Okui MA,
Kouno Y, Nakano K

Published in:
Cureus, 2023



Vulvodynia test pain score before and after laser treatment.

Short-Term Effects of an Erbium/ Neodymium Laser Combination in Superficial Dyspareunia: A Pilot Study

Authors: Gambacciani M & Fidicicchi T

Published in: Climacteric, 2022

1. A NOVEL COMBINATION LASER THERAPY FOR SUPERFICIAL DYSPAREUNIA

This prospective pilot study aimed to evaluate the effects of combining Nd:YAG laser with vaginal erbium laser (VEL), as a non-ablative photothermal therapy for superficial dyspareunia in postmenopausal women (PMW) suffering from genitourinary syndrome of menopause (GSM).

2. SINGLE VS. DUAL TREATMENT COMPARED BEFORE AND AFTER 3 SESSIONS


Two groups of sexually active PMW reporting superficial dyspareunia were selected: one (15 patients, VEL) was treated using an Er:YAG laser (XS Fotona SMOOTH; Fotona, Ljubljana, Slovenia) with a wavelength of 2940 nm; in the other group (15 patients, VEL + Nd:YAG), this treatment was followed by Nd:YAG laser (Fotona SP Dynamis, PIANO mode) treatment. Treatment consisted of three laser applications at 30-day intervals. Symptoms were assessed before, after each laser application and after 1 and 3 months from the end of the treatment, using the subjective visual analog scale (VAS) for superficial dyspareunia.

3. THE VEL + ND:YAG GROUP SHOWED GREATER IMPROVEMENT

The results of this study showed that both groups achieved a rapid and significant improvement of superficial dyspareunia over time ($p < 0.001$) independently from age and years since menopause. The VEL + Nd:YAG group showed a greater improvement of superficial dyspareunia ($p < 0.001$); this difference was evident since the first treatment and remained stable over time.

4. COMBINING ND:YAG WITH VEL OFFERS BENEFITS FOR TREATING SUPERFICIAL DYSPAREUNIA

The addition of Nd:YAG to the vaginal erbium laser (VEL) protocol may induce greater improvement of superficial dyspareunia in postmenopausal women with GSM.



Mean visual analog scale (VAS) score over time for the two treatment groups – vaginal erbium laser (VEL) group and VEL + Nd:YAG group. T0, baseline; L1, laser session 1; L2, laser session 2; L3, laser session 3; T1, 1 month after treatment; T3, 3 months after treatment.

Superficial Dyspareunia Treatment with Hyperstacking of Er:YAG SMOOTH Laser: A Short-Term, Pilot Study in Breast Cancer Survivors

1. TREATING SUPERFICIAL DYSPAREUNIA IN POSTMENOPAUSAL BREAST CANCER SURVIVORS

The purpose of this study was to evaluate the effects of a modified Vaginal Erbium Laser (VEL) protocol with hyperstack mode on the vaginal vestibulum and introitus to treat superficial dyspareunia in postmenopausal breast cancer survivors suffering from genitourinary syndrome of menopause (GSM).

2. ENHANCING THE VEL PROTOCOL WITH A SECOND STEP OF ERBIUM HYPERSTACKING

This prospective, randomized pilot study analyzed two groups of postmenopausal women suffering from superficial dyspareunia. 34 women (VEL group) were treated with 2,940 nm Er:YAG laser (XS Fotona SMOOTH; Fotona, Ljubljana, Slovenia), while a second group of 34 patients (hyperstack group) received the same treatment along with a modified second step of the VEL protocol for the treatment of the vestibulum and introitus, which consisted of hyperstacked subablative, long pulses with very low fluence. For each group, three laser applications at 30-day intervals were performed. Symptoms were assessed before, after each application, and after 1 and 3 months from the last laser application, using the visual analog scale score for superficial dyspareunia.

3. RESULTS SHOW GREATER AND MORE PERSISTENT IMPROVEMENT IN HYPERSTACK GROUP

The results of this study showed that superficial dyspareunia improved in both groups over time ($P < 0.001$), regardless of age and years since menopause status. The reduction in the visual analog scale score after the third laser application was 58% in the VEL group versus 73.5% in the hyperstack group. Since the first of the three laser sessions, the hyperstack group showed more notable ($P < 0.001$) and persistent improvement of superficial dyspareunia symptoms.

4. HYPERSTACK TREATMENT LEADS TO MORE SIGNIFICANT IMPROVEMENT


Adding a hyperstack treatment protocol to the standard VEL treatment may enhance the beneficial effects on superficial dyspareunia in breast cancer survivors. The hyperstack treatment of the introitus and vestibulum leads to a more significant improvement in superficial dyspareunia than VEL treatment alone.

Authors: Fidecicchi T,
Gaspar A, Gambacciani M

Published in:
Menopause, 2022



OPEN ACCESS



Mean VAS score over time for the two treatment groups. T0, baseline; L1, laser session 1; L2, laser session 2; L3, laser session 3; T1, 1 month after treatment; T3, 3 months after treatment.

Efficacy and Safety of Non-ablative Vaginal Er:YAG Laser Treatment as a Novel Surgical Treatment for Overactive Bladder Syndrome: Comparison with Anticholinergics and β 3-adrenoceptor Agonists

1. IMPROVEMENT OF OAB SYMPTOMS

According to this large study with 150 patients, Er:YAG laser protocol (Dynamis, Fotona, Slovenia) demonstrated comparable efficacy to anticholinergics (fesoterodine, 4 mg) or β 3-adrenoceptor agonists (mirabegron, 25 mg). Compared to both medicines, the Er:YAG laser was the only therapy to promote vaginal cell synthesis and improve VHIS scores.

2. BETTER VAGINAL HEALTH STATUS

Er:YAG laser therapy has been shown to significantly improve the vaginal tissue and its overall health status.

3. DIFFERENT SAFETY PROFILE

There have been no adverse effects reported in the laser group, but there were some observed in the pharmacotherapy groups. Mouth dryness, associated with the use of medications for example, led to a desire to change the treatment in up to 22% of patients.

4. NEW INSIGHTS INTO MECHANISMS OF ACTION

The results of the laser group may indicate the presence of a relationship between the vaginal condition and OAB, which from a different perspective can be considered a pathway that closely connects the vagina and bladder via the OAB mechanism. Er:YAG laser therapy can improve OAB symptoms through a different mechanism than that involved in pharmacotherapy.

Authors: Okui NP

Published in: World Journal of Urology, 2019



Exploring the Impact of Non-Ablative Erbium Laser Therapy on Recurrent Vaginal Candidiasis

Authors: Gaspar A, Calderon A, Vargas Mora J, Silva J, Bojanini JF, Araujo MJ, Lazzalea Geada L, Ivanova E, Helvacioğlu Y, Peña Coello P, Zelaschi D, Lucas MF, Mitraud L, Carneiro V, Cogorno M, Novakov Mikic A, Vasilescu M

Published in:
Lasers in Surgery and Medicine, 2025



1. TESTING LASER THERAPY FOR RECURRENT VAGINAL CANDIDIASIS (RVVC)

This study aimed to assess the safety and effectiveness of non-ablative Er:YAG vaginal laser therapy in treating women with recurrent vulvovaginal candidiasis (RVVC), a condition marked by multiple yeast infections per year. The goal was to evaluate its ability to reduce both symptoms and the presence of *Candida* and other pathogens.

2. MULTI-CENTER STUDY WITH SYMPTOM AND PATHOGEN MONITORING


A total of 167 women with RVVC from 17 gynecological centers in 11 countries underwent four non-ablative vaginal Er:YAG laser sessions (SP Dynamis, Fotona, Slovenia) over four months. The study tracked microbiological cultures and five key symptoms (burning, itching, dyspareunia, dysuria, discharge) at baseline, 3 months, and 9 months post-treatment. Patient satisfaction and adverse effects were also recorded to evaluate safety and acceptability.

3. LASER REDUCED CANDIDA AND IMPROVED SYMPTOMS SIGNIFICANTLY

The therapy led to significant improvement in all bothersome symptoms, with complete symptom resolution (VAS = 0) in 38%–74% of women depending on the symptom, and reductions maintained at 9 months. *Candida albicans* prevalence dropped from 80% to 30%, with a complete pathogen elimination in 64% of participants. Patients reported high satisfaction (86% satisfied/very satisfied), and only minor, transient adverse effects were observed.

4. PROMISING, SAFE ALTERNATIVE TO CONVENTIONAL ANTIFUNGAL TREATMENTS

Non-ablative vaginal Er:YAG laser therapy appears to be a safe and effective treatment for RVVC, showing durable symptom relief and significant pathogen reduction. It may serve as a promising non-pharmacological option, especially for patients with recurrent infections resistant to standard treatments.



Microbiological findings in vaginal swabs of participants during the study. Data are given as prevalence of specific species (B, baseline; FU1, after 3 months; FU2, after 9 months).

Effects of Non-ablative Vaginal Er:YAG Laser Treatment for Interstitial Cystitis/Bladder Pain Syndrome: A Case Series (UNICORN-2 Study)

1. EXAMINING THE EFFECTIVENESS OF NON-ABLATIVE ER:YAG LASER FOR PATIENTS WITH IC/BPS

There are no established treatments for interstitial cystitis/bladder pain syndrome (IC/BPS). The authors conducted a study to verify the effectiveness of non-ablative vaginal Er:YAG laser (VEL) treatment for patients with IC/BPS who were resistant to conventional treatments.

2. A YEAR-LONG STUDY OF 12 IC/BPS PATIENTS

A total of 12 patients without improvement after several treatments underwent nonablative vaginal Er:YAG laser treatment (XS Dynamis, Fotona, Slovenia) once a month for 12 months. The numeric rating scale-11 (NRS-11), O'Leary-Sant interstitial cystitis symptom and problem indexes (ICSI and ICPI), functional bladder capacity, and daily urinary frequency were recorded.

3. RESULTS SHOW IMPROVEMENT IN 9 OF 12 PATIENTS


VEL treatment demonstrated efficacy for both ulcerative and non-ulcerative patients with IC/BPS. The response rate was 75% (9 out of 12). The NRS-11 scores and ICSI and ICPI improved in all responders. The bladder capacity and urinary frequency also normalized. The residual effect lasted for 18 months from the first treatment, without long-term side-effects.

4. A PROMISING TREATMENT OPTION FOR PATIENTS WITH IC/BPS

Nonablative vaginal Er:YAG laser treatment is a safe and effective treatment for patients with IC/BPS.

Authors: Okui NP, Okui M, Vizintin Z

Published in: *Climacteric*, 2020



Effect of VEL treatment according to (a) the numeric rating scale-11 (NRS-11), (b) the O'Leary-Sant interstitial cystitis index (ICSI), (c) the O'Leary-Sant interstitial cystitis problem index (ICPI), (d) functional bladder capacity (IVIL) in ml and (e) daily urinary frequency. The x-axis of all graphs indicates time, showing progress from before VEL treatment to 1, 3, 6, 9, 12, 15, and 18 months.

Er:YAG Treatment for Relief of Long-term Symptoms Related to Episiotomy Scars - 1-Year Follow-up

Authors: Novakov Mikic A,
Pajk F, Vizintin Z

Published in: *European
Gynecology and
Obstetrics*, 2022



1. ASSESSING THE EFFICACY OF ER:YAG TREATMENT FOR EPISIOTOMY SCAR SYMPTOMS

The purpose of this study was to evaluate Erbium:YAG (Er:YAG) laser treatment for relief of long-term symptoms related to episiotomy scars.

2. 110 PATIENTS RECEIVED THREE ER:YAG LASER TREATMENT SESSIONS IN A TWO-STEP PROTOCOL


This single-arm study included patients with episiotomy scars complaining of at least one of the following: dyspareunia, pain while sitting, pain at pressure, pulling, bumps at perineum, and bleeding after intercourse. 110 patients aged 22–50 years (mean age 33 years) received three Er:YAG laser treatment sessions (XS Dynamis, Fotona, Slovenia) in a two-step protocol: full-spot cold ablation along the scar, and fractional ablation across the whole episiotomy surface.

3. RESULTS SHOWED SIGNIFICANT IMPROVEMENT WITH MINIMAL SIDE EFFECTS


Improvement and side effects were monitored at every treatment and 3 and 12 months after the last procedure. Average improvement increased with each treatment session and was maintained during 12 months of follow-up (average improvement at 12 months was 9.1 ± 1.1 on a 0–10 scale). All patients achieved improvement and 52.7% became symptom free. Average pain during the procedure (without anesthesia) was 5.4/10. Side effects were mild and transient.

4. LASER TREATMENT FOR EPISIOTOMY SCARS IS AN EFFECTIVE ALTERNATIVE TO SURGERY

The study confirmed that Erbium laser treatment is an excellent candidate as a less invasive alternative to surgery for relief of long-term symptoms related to episiotomy scars.



Two-step protocol for Er:YAG laser resurfacing of episiotomy scar. A) Full spot cold ablation along the scar with non-overlapping pulses. B) Fractional ablation across the whole episiotomy surface with 2 cm margins. C) Immediately after the procedure.



Improvement in episiotomy scar symptoms (mean±SD) after each of three laser treatment sessions (L1, L2, L3) and at 12 months follow-up (FU).

Sutureless Laser Labiaplasty of Labia Minora

Authors: Bizjak Ogrinc U
& Sencar S

-

Published in:
Sexual Medicine, 2021



1. EXAMINING THE EFFICACY AND SAFETY OF SUTURELESS LASER LABIAPLASTY

The purpose of this study is to report on a “sutureless” laser labiaplasty and to evaluate the efficacy and safety of this technique. Vaginal labiaplasty, the surgical reduction of the labia minora as a treatment for labia hypertrophy, has become a common procedure, with many different techniques yet no optimal approach suggested.

2. A RETROSPECTIVE ANALYSIS OF 80 FEMALE PATIENTS

A retrospective chart review analysis of 80 female patients who underwent laser labiaplasty with 2940 nm Er:YAG laser (SP Dynamis, Fotona, Slovenia) between February 2015 and April 2018 was conducted. The labiaplasty procedure was carried out in around 30-40 minutes, and there were no intraoperative complications. The patients were asked about or checked for side effects and answered a questionnaire regarding their satisfaction.

3. THE MAJORITY OF PATIENTS SHOWED HIGH SATISFACTION, WITHOUT SIDE EFFECTS

The majority of women (71 or 89%) did not experience any side effects, 7 (9%) developed wound infection, bleeding was reported by 1 patient, and 1 woman reported hematoma formation. All of the patients reported high satisfaction. There were no partly satisfied or dissatisfied patients.

4. SUTURELESS LASER LABIAPLASTY CAN BE CONSIDERED SAFE AND EFFECTIVE

Sutureless laser labiaplasty is a safe and effective way of improving women's lives and is associated with a high degree of patient satisfaction.



Patient before and 3 weeks after procedure.

Effectiveness and Safety of Ablative Er:YAG Laser Treatment for External Genital Warts

1. EXAMINING THE USE OF ER:YAG LASER FOR REMOVING GENITAL WARTS

The aim of this study is to evaluate the effectiveness and safety of using ablative Er:YAG laser for removal of external genital warts (EGW), also called condylomata acuminata (CA).

2. MORE THAN 100 FEMALE PATIENTS INCLUDED IN RETROSPECTIVE COHORT STUDY

This was a retrospective cohort study performed at the Juna Gynecology Clinic in Ljubljana, Slovenia. A total of 133 female patients older than 18 years (mean age 39.6 ± 12.9 years, range: 19–80) that were clinically diagnosed with EGW and were treated with ablative Er:YAG laser (Dynamis, Fotona, Slovenia) between January 2012 and December 2017 were included in the study. EGW had been present from one to seven months, with a mean presence of 2.1 ± 2.0 months. The majority of the warts were on the labia majora with some also on the mons pubis. The size of the lesions was 2–8 mm.

3. THE MAJORITY OF PATIENTS SHOWED COMPLETE CLEARANCE, WITHOUT RECURRENCE

The majority of the 116 patients who completed therapy (74 patients) received only one treatment and 82 of the patients ($n = 95$) showed complete clearance of the lesions, without recurrence observed to date of analysis. Complete clearance was achieved after an average of 1.33 treatment sessions. Recurrence was reported by 21 patients (18). Recorded adverse effects of laser treatment were mild and transient.

4. ER:YAG LASER IS A SIMPLE, QUICK AND SAFE PROCEDURE FOR REMOVAL OF EGW

Er:YAG laser removal of EGW is a simple, quick and safe procedure, particularly suitable for large volume EGW or those that are located in anatomical sites difficult to access by other techniques.

Effectiveness (Complete Clearance (CC)) of Er: YAG laser treatment within the age groups.

Age group	No. of patients [n]	Mean no. of treatments (95% CI)	Patients requiring single treatment [n, (%)]	Effectiveness of treatment CC [n, (%; 95% CI)]	Mean no. of treatments needed for CC ^b (95% CI)
19-29	26	1.96 (1.43-2.49)	14 (54.8)	21 (80.7; 73.6-89.9)	1.62 (1.11-2.13)
30-39	35	1.63 (1.26-1.99)	24 (68.6)	27 (77.1; 79.5-84.8)	1.19 (0.94-1.43)
40-49	31	1.45 (1.15-1.75)	21 (67.7)	29 (93.5; 89.1-98.0)	1.34 (1.09-1.60)
50-59	12	1.25 (0.96-1.54)	9 (75.0)	10 (83.3; 76.6-90.1)	1.10 (0.87-1.33)
60-69	8	1.50 (1.05-1.95)	4 (50.0)	4 (50.5; 40.9-59.1)	1.00 (1.00-1.00)
70-80	4	1.50 (0.58-2.42)	2 (50.0)	4 (100; 100-100)	1.50 (0.58-2.42)
Overall	116	1.60 (1.42-1.78)	74 (63.8)	95 (81.9; 74.9-88.9)	1.33 (1.17-1.48)

Authors: Bizjak Ogrinc U
& Sencar S

Published in: Slovenian
Medical journal, 2020



Safety of Vaginal Erbium Laser: A Review of 113,000 Patients Treated in the Past 8 Years

Authors: Gambacciani M, Cervigni A, Gaspar A, Novakov Mikić A, Gaviria PJE, Koron N, Vizintin Z

Published in: *Climacteric*, 2020



OPEN ACCESS



1. EVALUATING THE FREQUENCY OF ADVERSE EFFECTS FROM VAGINAL ERBIUM LASER (VEL)

The aim of this study was to obtain information on the frequency of occurrence of adverse effects (AEs) related to vaginal erbium laser (VEL) treatment.

2. LARGEST SURVEY ON AES FOR PROCEDURES PERFORMED IN GYNECOLOGY WITH EB DEVICES

A global survey was conducted among practitioners using the non-ablative VEL treatment. Users were invited to provide the number of patients treated with VEL (Fotona, Slovenia) and the number of observed laser-related AEs.

The survey was conducted from August 2018 to April 2019. Responses from 535 practitioners were collected, with a total of 113,174 patients treated in the period from 2012 to 2019.

3. AES WERE MILD TO MODERATE, TRANSIENT AND APPEARED WITH LOW FREQUENCIES.

Out of 535 respondents, 160 (30%) shared detailed information about the indications they treated in a population of 62,727 patients, whereas 188 respondents (35%) provided information on the frequency of AEs observed in their treated population of 43,095 patients. All observed AEs were mild to moderate, transient and appeared with low frequencies.

4. VAGINAL ERBIUM LASER (VEL) TREATMENTS APPEARS TO BE VERY SAFE

Minimally invasive thermal-only laser treatments using the non-ablative VEL procedure appear to be safe, and carry a very low risk profile.

Reported adverse effect (AEs), mean frequency of AE occurrence, range of reported frequencies, and calculated overall frequency.

Adverse effect	Number of respondents reporting the AE (n)	Mean of frequencies (%)	Range of frequencies (%)	BCa bootstrap interval ^a	24 weeks frequencies (%) ^b
Vaginal discharge	47	6.53	0.00-100	3.69-9.67	4.01
Edema	23	3.72	0.00-100	1.80-5.86	3.45
Pain (during treatment)	30	1.92	0.00-50.0	1.09-2.92	1.44
Pinpoint bleeding	33	1.55	0.00-50.0	0.87-2.36	1.16
Dryness	14	0.22	0.00-7.37	0.10-0.36	0.48
De novo urinary incontinence	13	0.28	0.00-14.3	0.12-0.49	0.21
Burns	7	0.10	0.00-10.0	0.02-0.22	0.16
Post-operative pain	7	0.47	0.00-37.7	0.07-1.06	0.10
Mild irritation of the introitus	4	0.56	0.00-70.0	0.007-1.70	0.44
Discoloration	2	0.10	0.00-16.7	0.003-0.32	0.02
Itching	2	0.06	0.00-10.0	0.001-0.24	0.01
Infection	4	0.03	0.00-3.33	0.001-0.07	0.01
Abnormal bleeding	1	0.04	0.00-6.67	0.04-0.16	0.005
Dyspareunia	1	0.004	0.00-0.69	0.04-0.17	0.002

^aBCa, bias-corrected and accelerated (BCa) bootstrap interval, based on 1000 bootstrap samples (999 for burns, 982 for introital irritation, 985 for infection, 866 for itching, 653 for abnormal bleeding, 637 for dyspareunia, 858 for discoloration); ^bcalculated as the number of AEs per patients included in the safety analysis (n=43,095)

Effects of Non-ablative Er:YAG Laser on the Skin and the Vaginal Wall: A Systematic Review of the Clinical and Experimental Literature

1. EVALUATING THE EFFECTS OF NON-ABLATIVE ER:YAG LASER ON THE SKIN AND THE VAGINAL WALL

The aim of this systematic review was to summarize current knowledge about the effects of non-ablative Er:YAG laser on the skin and vaginal wall.

2. A REVIEW OF STUDIES FROM MEDLINE, EMBASE, COCHRANE, AND THE WEB OF SCIENCE

Studies investigating objectively measured effects of non-ablative Er:YAG laser on the skin or vaginal wall were included. The authors identified in vitro or ex vivo studies on human cells or tissues, studies in rats, and clinical studies. Most studies were on the skin (n = 11), while the rest were on the vagina (n = 4). Owing to the lack of methodological uniformity, no meta-analysis could be performed and therefore results were presented as a narrative review.

3. RESULTS SHOW A POSITIVE RESPONSE IN MULTIPLE OBJECTIVELY MEASURED EFFECTS

Although the methods used were not comparable, there were demonstrable effects in all studies. Immediately after application, an increase in superficial temperature, partial preservation of epithelium and subepithelial extracellular matrix coagulation were documented. Later, an increase in epithelial thickness, inflammatory response, fibroblast proliferation, an increase in the amount of collagen, and vascularization were described.

4. ER:YAG LASER PRODUCES POSITIVE EFFECTS WITHOUT EPITHELIAL ABLATION

Er:YAG laser energy may induce changes in the deeper skin or vaginal wall, without causing unwanted epithelial ablation. Laser energy initiates a process of cell activation, production of extracellular matrix, and tissue remodeling.

Authors: Hympanova L,
Mackova K, El-Domyati M,
Vodegel E, Roovers J,
Bosteels J, Krofta L, Deprest J

Published in: *International
Urogynecology Journal*, 2020







List of Published Clinical Studies

Literature

STRESS URINARY INCONTINENCE (SUI)

1. Lukanovic D, Shah G, Matjasic M, Phillips C. The use of energy-based devices for the treatment of stress urinary incontinence: A systematic review and meta analysis of the randomised sham-controlled trials. *Int Urogynecol J*, 2026
2. Strumbelj T & Logar T. Combination of non-ablative Er:YAG laser and magnetic stimulation for the treatment of urinary incontinence: A single-arm pilot study. *Eur Gynecol Obstet*, 2025
3. Erel CT, Betul I, Erkan O, Gokmen N, Gambacciani M, Gaspar A, et al. Combined intraurethral and intravaginal Er:YAG laser (UEL + VEL) therapy vs. intraurethral (UEL) alone treatment for stress urinary incontinence? A multicenter retrospective cohort study, real world data from the VELA centers. *Lasers Med Sci*, 2025
4. Erel CT, Phillips C, Shah G, Gamper M, Kuszka A, Chandrakumaran K, Viereck V. Vaginal erbium laser for the treatment of moderate stress urinary incontinence: A multicentre randomised sham – controlled trial. *BJOG*, 2025
5. Pancholia V, Pancholia T, Talaber I, Vizintin Z. The impact of IncontiLase Er:YAG laser treatment on the quality of life of women with stress urinary incontinence. *Adv Urol*, 2025
6. Okui N. Laser treatment for urinary incontinence in elite female athletes analyzed using a discrete mathematics approach. *Sci Rep*, 2025
7. Yan H, Wang J, Ding Y, Huang G, Ding H, Zhao W, Ma Y. The efficacy and safety of Er:YAG laser therapy for stress urinary incontinence: A systematic review and meta-analysis. *Lasers Surg Med*, 2025
8. Page A-S, Borowski E, Bauters E, Housmans S, Van der Aa F, Deprest J. Vaginal erbium laser versus pelvic floor muscle training for stress urinary incontinence: A randomised controlled trial. *Int Urogynecol J*, 2025
9. Wang X, Zhang Z, Meng L, Xu S, Zheng J, Wang H, Lv J, Zhang Z, Yuan X, Zhang Y. Efficacy and safety of non-ablative Er:YAG laser for mild to moderate stress urinary incontinence: A prospective, multicenter, randomized, sham-controlled clinical trial. *Lasers Med Sci*, 2025
10. Lia M, Pilat P, Weydandt L, Baessler K, Kempe T, Aktas B. The effect of vaginal Er:YAG laser therapy on pelvic floor symptoms in women with stress urinary incontinence: A single-center cohort study. *Lasers Surg Med*, 2025
11. Okui N. & Okui M. 2024. Unsupervised clustering analysis of treatment strategies for elite female athletes with severe stress urinary incontinence: Focusing on competition return and SUI improvement. *Int Urol Nephrol*, 2024
12. Okui N. The treatment selection for a 36-year-old woman with stress urinary incontinence using a discrete mathematical approach: A case report. *Cureus*, 2024



13. Okui N. Innovative decision making tools using discrete mathematics for stress urinary incontinence treatment. *Sci Rep*, 2024



14. Tan Y, Zhang Y, An J, Xu X, Deng J, Chen B & Pan W. Safety and efficacy of erbium: yttrium-aluminum-garnet laser treatment in Chinese women with mild-to-moderate stress urinary incontinence. *J Women's Health*, 2024



15. Lee P, Perruzza D, Edell H, Jarvi S, Kim K, Sultana R, Alavi N et al. Double-blind randomized controlled trial of Er:YAG vaginal laser to treat female stress urinary incontinence. *Am J Obstet Gynecol*, 2024



16. O'Reilly BA, Viereck V, Phillips C, Tooze-Hobson P, Kuhn A, Athanasiou S, Lukanovic A, Palmer B, Dahly D, Daykan Y, Cardozo L. Vaginal erbium laser treatment for stress urinary incontinence: A multicenter randomized sham-controlled clinical trial. *Int J Gynaecol Obstet*, 2023



17. da Fonseca LC, Giarreta FBA, Peterson TV, Locali PKM, Baracat EC, Ferreira EAG, Haddad JM. A randomized trial comparing vaginal laser therapy and pelvic floor physical therapy for treating women with stress urinary incontinence. *Neurourol Urodyn*, 2023



18. Okui N, Erel T, Okui MA. Analysis of predictive factors for return to sports in female athletes with stress urinary incontinence. *Cureus*, 2023



19. Tseng Y-L & Su C-F. Efficacy and safety of intraurethral Erbium:YAG laser treatment in women with stress urinary incontinence following failed intravaginal laser therapy: A retrospective study. *Lasers Med Sci*, 2023



20. Li P-C & Ding D-C. Comparison of Er:YAG and CO₂ laser therapy for women with stress urinary incontinence. *Lasers Surg Med*, 2023



21. Okui N, Ikegami T, Novakov Mikic A, Okui M, Gaspar A. Long-term improvement in urinary incontinence in an elite female athlete through the laser treatment: A case report. *Cureus*, 2023



22. Erel CT, Gambacciani M, Ozcivit Erkan IB, Gokmen Inan N, Hamzaoglu Canbolat K, Fidecicchi T. SUI in postmenopausal women: Advantages of an intraurethral + intravaginal Er:YAG laser. *Climacteric*, 2023



23. Junmin YUE, Haoyu YAO, Tao YANG, Kunfeng DU, Shasha QI. Efficacy and safety of transurethral erbium YAG laser in the treatment of postmenopausal female stress urinary incontinence. *J Clin Urol*, 2023



24. Long C-Y, Wu P-C, Chen H-S, Lin K-L, Loo Z, Liu Y, Wu C-H. Changes in sexual function and vaginal topography using transperineal ultrasound after vaginal laser treatment for women with stress urinary incontinence. *Sci Rep*, 2022



25. Novakov Mikic A, Lepes Bingold B, Korosec B, Vizintin Z. Erbium laser thermo-therapy for female stress urinary incontinence – 18 months follow-up. J LAHA, 2022



26. Gaspar A, Koron N, Silva J, Brandi H. Vaginal erbium laser for treatment of stress urinary incontinence: Optimization of treatment regimen for a sustained long-term effect. Lasers Med Sci, 2022



27. Pancholiya V, Pandya MR, Patel KK. Non-ablative Er:YAG laser treatment for stress urinary incontinence (SUI). Ind J Obstr Gyn Research, 2022



28. Okui N, Miyazaki H, Takahashi W, Miyauchi T, Ito C, Okui M, Shigemori K, Miyazaki Y, Vizintin Z, Lukac M. Comparison of urethral sling surgery and non-ablative vaginal Erbium:YAG laser treatment in 327 patients with stress urinary incontinence: A case-matching analysis. Lasers Med Sci, 2021



29. Erel CT, Fistonc I, Gambacciani M, Oner Y, Fistonc N. Er:YAG laser in hysterectomized women with stress urinary incontinence: A VELA retrospective cohort, non-inferiority study. Climacteric, 2020



30. Erel CT, Carazo Fernandez LD, Inan D, Makul M. Er:YAG laser treatment of urinary incontinence after failed TOT/TVT procedures. Eur J Obstr Gynecol, 2020



31. Okui N. A two-year study of a non-ablative erbium YAG laser procedure for stress urinary incontinence with a focus on the sexual function ~ A comparison with the tension-free vaginal tape procedure. Jap J Med, 2020

32. Su C-F, Chen G-D, Tsai H-J. 2019. Preliminary outcome of non-ablative vaginal Erbium laser treatment for female stress and mixed urinary incontinence. Taiwan J Obstet Gynecol, 2019



33. Kuszka A, Gamper M, Walser C, Kociszewski J, Viereck V. Erbium:YAG laser treatment of female stress urinary incontinence: midterm data. Int Urogynecol J, 2019



34. Erel D, Inan D, Mut A. Predictive factors for the efficiency of Er:YAG laser treatment of urinary incontinence. Maturitas, 2019



35. Lin K-L, Chou S-H, Long C-Y. Effect of Er:YAG laser for women with stress urinary incontinence. Biomed Res Int, 2019



36. Jian-wei LV, Ting-ting LV, Jun-wen SI, Wei-Lin FANG, Chen JIANG, Jing LENG, Wei XUE. Non-ablative transurethral Erbium YAG laser in treatment of female stress urinary incontinence. J Modern Urol, 2018

37. Lin HY, Tsai HW, Tsui KH, An YF, Lo CC, Lin ZH, Liou WS, Wang PH. The short-term outcome of laser in the management of female pelvic floor disorders: Focus on stress urine incontinence and sexual dysfunction. Taiwan J Obstet Gynecol, 2018



38. Okui N. Comparison between erbium-doped yttrium aluminum garnet laser therapy and sling procedures in the treatment of stress and mixed urinary incontinence. World J Urol, 2018



39. Blaganje M, Scepanovic D, Zgur L, Verdenik I, Pajk F, Lukanovic A. Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol, 2018



40. Fistonc I & Fistonc N. Baseline ICIQ-UI score, body mass index, age, average birth weight, and perineometry duration as promising predictors of the short-term efficacy of Er:YAG laser treatment in stress urinary incontinent women: A prospective cohort study. Lasers Surg Med, 2018



41. Lin Y-H, Hsieh W-C, Huang L, Liang C-C. Effect of non-ablative laser treatment on overactive bladder symptoms, urinary incontinence and sexual function in women with urodynamic stress incontinence. Taiwan J Obstet Gynecol, 2017



42. Gaspar A & Brandi H. Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency). Lasers Med Sci, 2017



43. Lapii GA, Yakovleva AY, Neimark AI. Structural reorganization of the vaginal mucosa in stress urinary incontinence under conditions of Er:YAG laser treatment. Bull Exp Biol Med, 2017



44. Lapii GA, Yu Yakovleva A, Neimark AI, Lushnikova EL. Study of proliferative activity of vaginal epithelium in women with stress urinary incontinence. Bull Exp Biol Med, 2017



45. Okui NP, Yoda K, Vizintin Z. Comparison of Erbium-YAG laser treatment with TVT and TOT in Asian women with SUI. Geriatr Med, 2017



46. Kulikov IA, Spokoyny LB, Gorbunova EA, Apolikhina IA. A method for photothermal tissue reconstruction using Er: YAG laser Fotona in modern gynecology. Obstr & Gynecol, 2017



47. Tien Y-V, Hsiao S-M, Lee C-N, Lin H-H. Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. Int Urogynecol J, 2016



48. Barber MA & Eguiluz I. Patient satisfaction with vaginal erbium laser treatment of stress urinary incontinence, vaginal relaxation syndrome and genitourinary syndrome of menopause. J LAHA, 2016



49. Fistonc N, Fistonc I, Gustek SF, Bilajac Turina IS, Marton I, Vizintin Z, Kazic M, Hreljac I, Perhavec T, Lukac M. Minimally invasive, non-ablative Er-YAG laser treatment of stress urinary incontinence in women — a pilot study. *Lasers Med Sci Science*, 2016



50. Pardo JI, Sola VR, Morales AA. Treatment of female stress urinary incontinence with Erbium-YAG laser in non-ablative mode. *Eur J Obstet Gynecol Reprod Biol*, 2016



51. Bizjak Ogrinc U, Sencar S, Lenasi H. Novel minimally invasive laser treatment of urinary incontinence in women. *Lasers Surg Med*, 2015



52. Khalafalla MM, Elbiaa AAM, Abdelazim IA, Hussain M. Minimal invasive laser treatment for female stress urinary incontinence. *Obstet Gynecol Int*, 2015



53. Fistonc N, Fistonc I, Lukanovic A, Findri Gustek S, Sorta Bilajac Turina I, Franic D. First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: Prospective cohort study. *Climacteric*, 2015



54. Bezmenko AA, El'kin GI, Shmidt AA, Koval' AA, Sibirev SA, Molchanov OL, Protoschak VV. Treatment of stress urinary incontinence with Er:YAG laser: Some biochemical parameters of connective tissue metabolism. *J Exper Clin Urol*, 2014



55. Bezmenko AA, Shmidt AA, Koval AA, Sibirev SA, Karpishchenko ZM, Gayvoronskikh DI. Morphological substantiation of applying the Er:YAG laser for the treatment of stress urinary incontinence in women. *J Obstet Woman's Dis*, 2014



56. Fistonc I, Findri-Gustek S, Fistonc N. Minimally invasive laser procedure for early stages of stress urinary incontinence (SUI). *J LAHA*, 2012



GENITOURINARY SYNDROME OF MENOPAUSE (GSM)

57. Pustotina O, Demkin V, Vizintin Z, Erel T, Regenyi P. Short-term effects of non-ablative erbium and neodymium/erbium laser combination treatment on genitourinary syndrome of menopause and the vaginal microbiome: A pilot study. *Eur Gynecol Obstet*, 2026



58. Zheng J, Li M, Chen Y, Zhang Z. Efficacy of non-ablative vaginal erbium laser for rUTI prevention in postmenopausal women. *Lasers Med Sci*, 2025



59. Abe H, Urabe F, Nakazono M, Kawaharada A, Kimura T. Vaginal laser therapy as a potential treatment option for postmenopausal women with recurrent cystitis: Initial experience from a single institution. *Lasers Surg Med*, 2025



60. Fidecicchi T & Gambacciani M. Hyaluronic acid and erbium laser for the treatment of genitourinary syndrome of menopause. *Climacteric*, 2024



61. Bayraktar E, Erel CT, Akturk H, Ozcivit Erkan IB, Hamid R, Alper E, Adaletli I, Urfalioglu M. A novel objective evaluation method, shear wave elastography, in the treatment of atrophic vaginitis by nonablative intravaginal Er:YAG laser, a randomized-sham controlled pilot study. *Menopause*, 2024



62. Panyawongudom N, Panyakhamlerd K, Suwan A. Number of vaginal lactobacilli in postmenopausal women with vaginal atrophy before and after treatment with erbium-YAG laser: A randomized sham-controlled trial. *BMC Women's Health*, 2023



63. Avul Z. & Guven CM. A study of the objective benefits and safety of Er-YAG laser in the treatment of genitourinary syndrome of menopause. *Lasers Med Sci*, 2023



64. Lin KL, Chou SH, Loo ZX, Liu YY, Cheng JC, Long CY. The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM). *Lasers Med Sci*, 2022



65. Gambacciani M, Albertin E, Torelli MG, Bracco GL, Casagrande AC, Martella L, Baiocchi G, Alfieri S, Russo N, Cervigni M. Sexual function after vaginal erbium laser: The results of a large, multicentric, prospective study. *Climacteric*, 2020



66. Gaspar A, Silva J, Calderon A, Di Placido V, Vizintin Z. Histological findings after non-ablative Er:YAG laser therapy in women with severe vaginal atrophy. *Climacteric*, 2020



67. Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. *Climacteric*, 2018



68. Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, Vizintin Z. Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: A pilot study. *Lasers Surg Med*, 2018



69. Gambacciani M & Palacios S. Laser therapy for the restoration of vaginal function. *Maturitas*, 2017



70. Gambacciani M & Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: A pilot study in breast cancer survivors. *Menopause*, 2017



71. Dobrokhotova YuE, Ilyina IYu, Venedkitova MG, Morozova KV, Suvorova VA, Zalesskaya SA. Er:YAG laser treatment for genitourinary disorders. *Obstet Gynecol*, 2017



72. Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. *Lasers Surg Med*, 2016



73. Bojanini JF. Treatment of genitourinary syndrome of menopause with Erbium:YAG laser: a prospective study of efficacy and safety of the treatment for women after menopause of natural origin and therapy-induced menopause in breast cancer survivors. *J LAHA*, 2016



74. Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: The second-generation thermotherapy for the genitourinary syndrome of menopause. *Climacteric*, 2015



75. Gambacciani M, Torelli MG, Martella L, Bracco GL, Casagrande AG, Albertin E, Tabanelli S, Viglietta M, D'Ambrogio G, Garone G, Cervigni M. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): An international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. *Climacteric*, 2015



76. Gambacciani M & Levancini M. Short term effect of vaginal erbium laser on the genitourinary syndrome of menopause. *Minerva Ginecol*, 2015



77. Bojanini JF & Mejia CAM. Laser treatment of vaginal atrophy in post-menopause and post-gynecological cancer patients. *J LAHA*, 2014



VAGINAL RELAXATION SYNDROME / VAGINAL LAXITY

78. Qi Y, Sun C, Zhou Y, Luo L, Wang C. Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators. *Am J Transl Res*, 2025



79. Alper E & Senai A. Impact of subablative Erb:Yag laser applications on vaginal resting and contraction pressures. *Med Bull Haseki*, 2023



80. Setyaningrum T, Tjokropawiro BA, Listiawan MY, Santoso B, Prakoeswa CRS. Treating vaginal relaxation syndrome using Erbium: Yttrium Aluminum Garnet fractional laser: A retrospective study. *Gynecol Minim Invasive Ther*, 2022



81. Sathaworawong A, Manuskiatti W, Phatihatthakorn C, Ungakornpairote C, Ng JN. The efficacy of erbium-doped yttrium aluminum garnet (Er:YAG) laser in the treatment of decreased sexual sensation: A randomized, placebo-controlled trial. *Lasers Med Sci*, 2021



82. Gaviria JE & Bucik M. 2021. G-Runner robotic vaginal probe for IncontiLase® and IntimaLase® treatment - a pilot study. *J LAHA*, 2021



83. Mitsuyuki M, Stok U, Hreljac I, Yoda K, Vizintin Z. Treating vaginal laxity using nonablative Er:YAG laser: A retrospective case series of patients from 2.5 years of clinical practice. *Sex Med*, 2020



84. Ahmed SM, Kotb HG, Yousef AM, Ahmed H. Effect of laser on pelvic floor strength and sexual satisfaction in women complaining of vaginal looseness: A randomized controlled trial. *Pol J Physiother*, 2019



85. Gaviria PJE, Korosec B, Fernandez J, Montero G. Up to 3-year follow-up of patients with vaginal relaxation syndrome participating in laser vaginal tightening. *J LAHA*, 2016



86. Pardo J & Sola Dalenz V. Laser vaginal tightening with non-ablative Er:YAG for vaginal relaxation syndrome. Evaluation of patient satisfaction. *J LAHA*, 2016



87. Gaviria PJE & Lanz LJA. Laser Vaginal Tightening (LVT) - evaluation of a novel non-invasive laser treatment for vaginal relaxation syndrome. *J LAHA*, 2012



PELVIC ORGAN PROLAPSE (POP)

- 88.** Page A-S, Borowski E, Bauters E, Housmans S, Van der Aa F, Deprest J. Vaginal erbium laser versus pelvic floor exercises for the treatment of pelvic organ prolapse: A randomised controlled trial. Eur J Obstet Gynecol Reprod Biol, 2024
- 89.** Novakov Mikic A, Lepes Bingold B, Hreljac I, Vizintin Z. Non-ablative vaginal erbium laser treatment of patients with cystocele and stress urinary incontinence – a retrospective study. Eur Gynecol Obstet, 2023
- 90.** Athanasiou S, Pitsouni E, Cardozo L, Zacharakis D, Petrakis E, Loutradis D, Grigoriadis T. Can pelvic organ prolapse in postmenopausal women be treated with laser therapy? Climacteric, 2021
- 91.** Bizjak Ogrinc U & Sencar S. Comment: 'Can pelvic organ prolapse in postmenopausal women be treated with laser therapy?' Climacteric, 2021
- 92.** Bizjak Ogrinc U & Sencar S. Non-ablative vaginal erbium YAG laser for the treatment of cystocele. It J Gynec Obstet, 2017
- 93.** Bizjak Ogrinc U & Sencar S. Laser treatment of higher grade cystocele. J LAHA, 2013



LICHEN SCLEROSUS

- 94.** Zivanovic I, Gamper M, Fesslermeier D, Bischofberger H, Viereck V. A randomized controlled trial to evaluate a novel dual laser therapy for vulvar lichen sclerosis: Exploratory study assessing the impact of menopausal status. Menopause, 2025
- 95.** Zivanovic I, Gamper M, Fesslermeier D, Walser C, Regauer S, Viereck V. Nd:YAG/Er:YAG dual laser compared with topical steroid to treat vulvar lichen sclerosis: A randomised controlled trial. BJOG: Int J Obstet Gynaecol, 2023
- 96.** Viereck V, Gamper M, Regauer S, Walser C, Zivanovic I. Nd:YAG/Er:YAG dual laser vs. topical steroid to treat vulvar lichen sclerosis: Study protocol of a randomized controlled trial. Arch Gynecol Obstet, 2023
- 97.** Kofler L, Charalambous A, Kussini J, Steinert M. Treatment of vulvar lichen sclerosis et atrophicus by ablative microspot erbium:YAG laser. J Dtsch Dermatol Ges, 2023
- 98.** Gomez-Frieiro M & Laynez-Herrero E. Use of Er:YAG laser in the treatment of vulvar lichen sclerosis. Int J Women's Dermatology, 2019



99. Bizjak Ogrinc U, Sencar S, Luzar B, Lukanovic A. Efficacy of non-ablative laser therapy for lichen sclerosus: A randomized controlled trial. J Obstet Gynaecol Can, 2019



VULVODYNIA & VULVAR PAIN CAUSED BY A SPECIFIC DISORDER

100. Okui N, Ikegami T, Erel CT. Neodymium laser treatment for overactive bladder and vulvodynia in Mayer-Rokitansky-Küster-Hauser syndrome patient: A case report. Cureus, 2024



101. Okui N & Okui MA. The importance of psychological assessment in the management of bladder pain syndrome/interstitial cystitis and vulvodynia: A case report. Cureus, 2024



102. Okui N & Okui MA. Mathematical approach to synergistic management of bladder pain syndrome/interstitial cystitis and vulvodynia: A case series utilizing principal component analysis, cluster analysis, and combination laser therapy. Cureus, 2024



103. Okui N, Okui M, Kouno Y, Nakano K, Gambacciani M. Efficacy of two laser treatment strategies for breast cancer survivors with genitourinary syndrome of menopause. Cureus, 2023



104. Okui N, Okui MA, Kouno Y, Nakano K. Laser treatment for patients with vulvodynia and interstitial cystitis/bladder pain syndrome: A case series (the UNICORN-3 study). Cureus, 2023



105. Gambacciani M & Fidecicchi T. Short-term effects of an erbium/neodymium laser combination in superficial dyspareunia: A pilot study. Climacteric, 2022



106. Fidecicchi T, Gaspar A, Gambacciani M. Superficial dyspareunia treatment with hyperstacking of erbium:yttrium-aluminum-garnet SMOOTH laser: A short-term, pilot study in breast cancer survivors. Menopause, 2022



107. Okui N, Okui M, Gambacciani M. Is Erbium/Neodymium laser combination therapy an effective treatment option for interstitial cystitis/bladder pain syndrome with vulvodynia? Cureus, 2022



108. Erel TC. Case report: Vulvodynia treated with Erbium:YAG laser. Eur J Obstet Gynecol Reprod Biol, 2018



OTHER GYNECOLOGICAL INDICATIONS

109. Gaspar A, Calderon A, Mora JV, Silva J, Bojanini JF, Araujo MJ, Geada LL, Ivanova E, Helvacioğlu Y, Coello PP, Zelaschi D, Lucas MF, Mitraud L, Carneiro V, Cogorno M, Novakov Mikic A, Vasilescu M. Exploring the impact of non-ablative erbium laser therapy on recurrent vaginal candidiasis. *Lasers Surg Med*, 2025



110. Okui N. & Okui M. Novel management of post-laparoscopic sacrocolpopexy-associated overactive bladder: A combined approach of vaginal natural orifice transluminal endoscopic surgery (vNOTES) mesh removal and Fotona laser therapy. *Cureus*, 2025



111. Okui N & Okui M. Discrete mathematics in dynamic network analysis: long-term efficacy evaluation of Fotona laser therapy for overactive bladder syndrome using clustering-based patient subgroup identification. *Cureus*, 2025



112. Okui N & Okui MA. Efficacy and safety of combination therapy with vaginal and urethral erbium-doped yttrium-aluminum-garnet (Er:YAG) laser for overactive bladder with urinary incontinence. *Cureus*, 2024



113. Okui N, Ikegami T, Erel CT. Non-ablative erbium (YAG) and neodymium (YAG) laser treatment for anal incontinence and vaginal atrophy: A case study. *Cureus*, 2024



114. Okui N. & Okui MA. Mesh extraction surgery and laser treatment for pain after mid-urethral sling surgery: A case series. *Cureus*, 2024



115. Okui N & Okui MA. Pathological insights on polypropylene mesh complications from laparoscopic sacrocolpopexy: A case series. *Cureus*, 2024



116. Okui N, Kouno Y, Nakano K & Okui MA. Evaluating non-ablative erbium yttrium aluminium garnet (YAG) laser treatment for polypropylene mesh-induced vaginal erosion: A case series. *Cureus*, 2024



117. Erel TC, Urfalioglu M, Hamid R, Kargin OA, Ozcivit Erkan IB, Bayraktar E, Adaletli I, Askin O. Ultrasonographic elastography, a new era showing the improvement of episiotomy scar treated with Er:YAG laser, a case-series. *Lasers Surg Med*, 2024



118. Novakov Mikic A, Pajk F, Vizintin Z. Erbium laser treatment for relief of long-term symptoms related to episiotomy scars - 1 year follow-up. *Eur J Obstet Gynecol*, 2022



119. Bizjak Ogrinc U & Sencar S. Sutureless laser labiaplasty of labia minora. *Sex Med*, 2021



- 120.** Ghelardi A, Marrai R, Bogani G, Sopracordevole F, Bay P, Tonetti A, Lombardi S, Bertacca G, Joura EA. Surgical treatment of vulvar HSIL: Adjuvant HPV vaccine reduces recurrent disease. *Vaccines*, 2021



- 121.** Okui N, Okui M, Vizintin Z. Effects of non-ablative vaginal erbium:YAG laser treatment for interstitial cystitis/bladder pain syndrome: a case series (UNICORN-2 study). *Climacteric*, 2020



- 122.** Bizjak Ogrinc U & Sencar S. Effectiveness and safety of ablative Er:YAG laser treatment for external genital warts. *Slov Med J*, 2020



- 123.** Okui N. Efficacy and safety of non-ablative erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: Comparison with anticholinergics and β 3-adrenoceptor agonists. *World J Urol*, 2019



- 124.** Pidal C. Er:YAG removal of vulvar, perineal, anal and intra-anal condilomas. *J LAHA*, 2019



- 125.** Okui N, Yoda KK, Vizintin Z. The first evaluation of erbium laser for treatment of female overactive bladder syndrome in comparison to standard medication therapies with 12 months follow-up. *Progress Med*, 2018

ADDITIONAL READING

- 126.** Okui N. Vaginal laser treatment for the genitourinary syndrome of menopause in breast cancer survivors: A narrative review. *Cureus*, 2023



- 127.** Lukac M, Zorman A, Lukac N, Perhavec T, Tasic B. Characteristics of non-ablative resurfacing of soft tissues by repetitive Er:YAG laser pulse irradiation. *Lasers Surg Med*, 2021



- 128.** Hympanova L, Mackova K, El-Domyati M, Vodegel E, Roovers J-P, Bosteels J, Krofta L, Deprest J. Effects of non-ablative Er:YAG laser on the skin and the vaginal wall: Systematic review of the clinical and experimental literature. *Int Urogynecol J*, 2020



- 129.** Gambacciani M, Cervigni M, Gaspar A, Novakov Mikic A, Gaviria J, Koron N, Vizintin Z. Safety of vaginal erbium laser: A review of 113,000 patients treated in the past 8 years. *Climacteric*, 2020



- 130.** Gaspar A, Kolodchenko Y, Gaviria J, Hreljac I, Vizintin Z. Does vaginal erbium laser affect subsequent vaginal deliveries? *Eur J Gynecol Obstet*, 2020



- 131.** Elia D, Gambiacciani M, Ayoubi JM, Berreni N, Bohbot JM, Descamps P, Druckmann R, Geoffrion H, Haab F, Heiss N, Rygaloff N, Russo E. Female urine incontinence: Vaginal erbium laser (VEL) effectiveness and safety. *Horm Mol Biol Clin Investig*, 2020



- 132.** Lukac M, Lozar A, Perhavec T, Bajd F. Variable heat shock response model for medical laser procedures. *Lasers Med Sci*, 2019



- 133.** Vizintin Z, Lukac M, Kazic M, Tettamanti M. Erbium laser in gynecology. *Climacteric*, 2015



- 134.** Vizintin Z, Rivera M, Fistonic I, Saracoglu F, Guimares P, Gaviria J, Garcia V, Lukac M, Perhavec T, Marini L. Novel minimally invasive VSP Er:YAG laser treatments in gynecology. *J LAHA*, 2012





Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....



Laser and Health Academy

Stegne 3
1000 Ljubljana
Slovenia, EU

www.laserandhealthacademy.com